Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Method of regulating cell metabolism or physiology

Subclass of:

435 - Chemistry: molecular biology and microbiology

435325000 - ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435377000 Method of altering the differentiation state of the cell 208
Entries
DocumentTitleDate
20130040389Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex - The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.02-14-2013
20130045533Modular transport platform for targeted delivery of therapeutic agents - The invention relates to a modular transport platform (MTP) for delivering active, diagnostic or research substances to predesigned intracellular compartments of target cells. The MTP includes functional modules within one molecule to accomplish one or more of the following: penetration of the modular transport platform into a target cell type, pH-dependent membrane disruption activity within the target cell, directed intracellular transport into preselected intracellular compartment, and delivery of a substance to be transported to the intracellular compartment. The modular transport platform includes the following modules: (1) a ligand module to target a specific receptor on the surface of the target cell; (2) an endosomolytic module that provides pH-dependent membrane disruption activity within the target cell; (3) an intracellular transport module to cause delivery of the MTP to a particular subcellular compartment; (4) a module for intracellular retention to ensure retention of the MTP within the subcellular compartment of the target cell; (5) a module for subcellular recognition; (6) a substance to be transported by the MTP; and (7) a carrier module for unifying the modules and coupling the modules with the transported substance.02-21-2013
20110207217Modulation of Gene Expression by Oligomers Targeted to Chromosomal DNA - Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.08-25-2011
20090203134REMEDY FOR NERVE CELL REGENERATION08-13-2009
20110183417POLYAMIDES FOR NUCLEIC ACID DELIVERY - The present invention provides a new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications. In particular, these vectors can be used for gene transfer applications. These new gene transduction vectors can achieve transfer efficiencies far greater to commercially available polymeric and liposomal gene transfer vectors while maintaining little or no toxicity in vitro. Their low in vitro toxicity makes them ideal candidates for in vivo use. The present invention also provides a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response. Furthermore, the unique polycationic structure of these polymers associates with many suitable biologically active molecule, including oligonucleotides and polypeptides and other compounds that poses multiple cationic sites. The polymer can act as a delivery vehicle for the associated biologically active molecule, in vivo or in vitro, to the cells of interest for the biologically active molecule. Complexes according to the invention or portions thereof, can comprise a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells. In some embodiments, cellular delivery molecules for use in the present invention may comprise one or more one or more polymers of the present invention, e.g., polyamides, dendritic macromolecules (polymers comprising an oligoamine shell and a cyclodextrin core), and carbohydrate-containing degradable polyesters.07-28-2011
20100144035Delivery system for nucleic acids using cationic polymer conjugates - The present invention relates to a delivery system for nucleic acid using a cationic polymer conjugate, and more specifically relates to a delivery system for nucleic acid comprising a cationic polymer conjugate prepared by conjugating hyaluronic acid or its derivative and polyethyleneimine, and a composition of delivering a nucleic acid into mammalian cell comprising a complex of the nucleic acid and a cationic polymer conjugate with electrostatic binding.06-10-2010
20120184035Methods and Compositions For Reprogramming Cells - Methods and compositions are provided for reprogramming cells. In an exemplary embodiment, fibroblasts are reprogrammed to adopt a skeletal, cardiac, or smooth muscle cell fate. Cell and tissue therapies using said methods and compositions are also disclosed.07-19-2012
20110195501ULTRASONICALLY INDUCED RELEASE FROM POLYMER VESICLES - Disclosed are methods of controllably permeabilizing polymersomes. Such methods are useful in permeabilizing polymersomes so as to effect controlled release of therapeutic or imaging agents to a particular location. Also disclosed are systems for controllably delivering various agents to particular locations via polymersomes and related polymersome-based methods for treating diseases and for imaging.08-11-2011
20110195500METHODS AND COMPOSITIONS FOR MITIGATING EOSINOPHILIC ESOPHAGITIS BY MODULATING LEVELS AND ACTIVITY OF EOTAXIN-3 - Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed.08-11-2011
20110195499UTILITY OF RET MUTANT IN DIAGNOSIS AND TREATMENT OF MELANOMA - The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant.08-11-2011
20090075376METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA - The invention provides methods for inhibiting tumor cell proliferation by inhibiting Fox M1B (also called Fox M1) activity in a tumor cell. The invention also provides FoxM1B siRNA molecules and pharmaceutical compositions comprising FoxM1B siRNA molecules, wherein the siRNA molecules can inhibit FoxM1B activity and can inhibit proliferation of tumor cells. The invention further provides methods for preventing tumor growth, progression or both in an animal comprising inhibiting FoxM1B activity using siRNA molecules or pharmaceutical compositions comprising FoxM1B siRNA molecules.03-19-2009
20080261304METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS - A double-stranded RNA, preferably a small, interfering (si)RNA or a siHybrid, to which cholesterol moieties are linked.10-23-2008
20090186410RNA SILENCING COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON'S DISEASE - The present invention relates to the discovery of an effective treatment for a variety of Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against single nucleotide polymorphisms (SNPs) in the Huntingtin (htt) gene encoding the dominant, gain-of-function mutant Huntington protein, thereby resulting in an effective treatment for the gain-of-function disease.07-23-2009
20120244618METHODS AND SYSTEMS FOR IDENTIFYING MICRO-RNA TARGETS AND SYNTHESIZING NOVEL MICRO-RNAS AND USES OF THE SAME - Method of identifying a microRNA-recognition element and of generating microRNAs are disclosed. System and computer programs for performing such methods are disclosed. Recombinant nucleic acid molecule comprising a heterologous coding sequences and one or more MREs are also disclosed as are isolated nucleic acid molecule comprising one or more MRE sequences and being free of a coding sequence operably linked to regulatory elements. MicroRNA generated by a methods of the invention and the usr of the microRNAs to downregulate gene expression are disclosed.09-27-2012
20130084639Bicyclic Derivatives as Modulators of Ion Channels - The present invention relates to bicyclic compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.04-04-2013
20130034902Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A)02-07-2013
20130040388CYTOSTATIC DRUG COMPOSITION - A drug composition containing as a drug substance a polymeric guanidine derivative based on a diamine containing oxyalkylene chains between two amino groups, with the guanidine derivative representing a product of polycondensation between a guanidine acid addition salt and a diamine containing polyalkylene chains between two amino groups, as well as the pharmaceutically acceptable salts thereof.02-14-2013
20090155903PHARMACEUTICAL COMPOSITION AND METHOD - The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ06-18-2009
20090068737Methods of inhibiting interleukin-17 receptor - Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.03-12-2009
20090155906CELL DIFFERENTIATION SUPPRESSING AGENT, METHOD OF CULTURING CELLS USING THE SAME, CULTURE SOLUTION, AND CULTURED CELL LINE - The object of the present invention is to provide a differentiation inhibiting agent which allows culture of a stem cell or an embryonic stem cell in an undifferentiated state without use of any feeder cell, a method for culturing using the same, a cell culture liquid using the same, and a cell prepared by culturing using this differentiation inhibiting agent. The present invention provides a differentiation inhibiting agent which comprises a low molecular weight compound, especially a tetrahydroisoquinoline derivative, as an active ingredient; a method for safely culturing a stem cell in large scale in undifferentiated state in the absence of feeder cell which comprises culturing a stem cell by using a tetrahydroisoquinoline derivative; a culture liquid for stem cells comprising a tetrahydroisoquinoline derivative; and a cell which is obtained by culture using a tetrahydroisoquinoline derivative as a differentiation inhibiting agent.06-18-2009
20090155905Composition and Method for Increasing Apoptosis in Cancer Cells - Disclosed are cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that significantly increases the effectiveness of the chemotherapeutic agent to destroy cancer cells. The invention also provides kits or systems for cancer therapy, comprising at least one peptide agent for inhibiting the anti-apoptotic effects of NF-kB and at least one chemotherapeutic agent for stimulating the cellular apoptotic pathway.06-18-2009
20090155904METHOD OF INHIBITING EXPRESSION OF TARGET MRNA USING SIRNA CONSISTING OF NUCLEOTIDE SEQUENCE COMPLEMENTARY TO SAID TARGET MRNA - A inhibition method of target mRNA expression includes: (a) obtaining binding energy of a double combination section on a dsRNA sequence of all combination comprising complementary nucleotides to a random target mRNA; (b) dividing the binding energy into four sections on the dsRNA sequence of each combination to obtain a difference of the mean binding energy between each section and convert into a score of a relative combination energy pattern; (c) selecting siRNA whose inhibition efficiency to target mRNA is expected to be high by applying the converted score to the dsRNA sequence with other factors that affect the efficiency of siRNA; and (d) inhibiting target mRNA expression using the selected siRNA. As a result, a researcher or an experimenter can analyze patterns of a relative binding energy on base sequences of unknown siRNA without actual experiments to determine whether the siRNA is effective or ineffective rapidly, thereby design and production efficiency of siRNA can be maximized and target mRNA can be effectively inhibited with efficient siRNA to the target mRNA.06-18-2009
20100041144Mammalian Cytokine; Related Reagents - Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.02-18-2010
20100041143HOLDING PETRI DISH, MICROINJECTION APPARATUS, AND MICROINJECTION METHOD - A holding petri dish used for a process of microinjection for introducing an introduced substance into an introduced-substance receiving body includes a well provided on a transparent material and a channel including an opening for holding the introduced-substance receiving body via suction, said opening being disposed on a side wall of the well.02-18-2010
20100041142ANTI-APOPTOTIC GENE SCC-S2 AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells.02-18-2010
20100267140SOLUBLE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF - The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF10-21-2010
20080286866NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing VEGFA, VEGFB, VEGFC, FIGF, or PGF gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a VEGF mRNA. In addition, the meroduplex may have at least one 5-methyluridine, locked nucleic acid, 2′-O-methyl, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a VEGF gene in a cell or in a subject to treat a VEGF-related disease.11-20-2008
20100093084METHOD FOR CREATING INTRACELLULAR ARTIFICIAL NANOSTRUCTURES IN SITU - A method of creating intracellular artificial nanostructures in situ, which employees a chemical precursor. The precursor does not self-assemble due to the presence of a cleavable motif linked to it. When the precursor comes inside live cells by an uptaking mechanism on the cell membrane, the cleavable motif is then to be removed by an enzymatic action of a first enzyme. Without the cleavable motif, the precursor now engages in a self-assembling process to form nanostructures within the live cells, which may cause formation of a hydrogel. Furthermore, the self-assembling process can be made reversible by employing a second enzyme which puts the cleavable motif back to the precursor, whereby dissolving the nanostructures into solution.04-15-2010
20130084638SCAFFOLD FOR VASCULAR ENDOTHELIAL CELL MIGRATION - A scaffold for vascular endothelial cell migration includes a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen. A method for producing a blood vessel uses this scaffold.04-04-2013
20090124008PEPTIDES FOR USE IN CULTURE MEDIA - The present invention provides peptides libraries which are useful for rapid identification of biologically active compounds. The invention further provides peptides which include cell-growth affecting peptides and peptides which enhance or inhibit production of cellular proteins. Many of the peptides of the invention may be produced in large quantity by recombinant techniques and formulated in culture medium to produce the desired effect on cultured cells and tissues. Certain of the libraries of the invention and the peptides identified in them are particularly useful in concatemer-based recombinant expression methods.05-14-2009
20110008889SERPIN DRUGS FOR TREATMENT OF HIV INFECTION AND METHOD OF USE THEREOF - The invention includes compositions comprising substantially purified serpin that are useful in methods for the treatment and prevention of HIV, HSV or HCV infection. The invention also includes methods for the treatment and prevention of HIV, HSV or HCV infection comprising contacting a composition of the invention with a human patient or treating HIV, HSV or HCV infection by introducing into a cell susceptible to HIV, HSV or HCV infection, a DNA molecule encoding a serpin.01-13-2011
20090042292B7-DC Variants - Compositions and methods for costimulating T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) are provided. Suitable compositions include variant B7-DC polypeptides, fragments and fusion proteins thereof. Variant B7-DC polypeptides have reduced binding affinity for the inhibitory PD-1 ligand and substantially retain the ability to costimulate T cells. Methods for using variant B7-DC polypeptides to stimulate immune responses in subjects in need thereof are provided.02-12-2009
20090042290METHOD OF MODIFYING A MACROMOLECULE WITHOUT PRIOR EXTRACTION FROM A SAMPLE - The present invention encompasses a method of modifying a macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.02-12-2009
20130089927Hematopoietic Cell E-Selectin/L-Selectin Ligand Polypeptides and Methods of Use Thereof - The invention features methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.04-11-2013
20090305409Liposome Capable of Effective Delivery of Given Substance Into Nucleus - Disclosed is a non-viral vector capable of delivering a given substance into the nucleus of a target cell effectively even when the target cells is a undividable cell such as a dendritic cell. A bilamellar liposome having a first lipid membrane and a second lipid membrane successively from the outside, the first lipid membrane having a membrane-fusing ability and the second lipid membrane having on its surface a nuclear transport peptide.12-10-2009
20090305410FLUORESCENT COMPOUNDS - The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.12-10-2009
20130071929Remedy for Chronic Inflammation and Antibody to be Used Therein - The invention provides a remedy for chronic inflammation and an anti-TNIIIA2 antibody to be used therein. The remedy includes an antibody recognizing TNIIIA2, that is a peptide derived from a partial sequence A2 of a human tenascin-C fibronectin III-like repetitive sequence and having the amino acid sequence RSTDLPGLKAATHYTITIRGVC (SEQ ID NO: 1).03-21-2013
20130071928NOVEL SHRNA MOLECULES AND METHODS OF USE THEREOF - The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.03-21-2013
20090298176siRNA targeting KRAS - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.12-03-2009
20090291498Biodegradable T-cell activation method - A biodegradable device for activating T-cells includes a biodegradable support and a binder attached to the biodegradable support, the binder having reactivity to one or more agents capable of binding to a T-cell surface antigen.11-26-2009
20090203138Small Interfering RNAs Targeting Feline Herpes Virus - The present application provides polynucleotides, compositions thereof and methods of treating feline herpes virus infections. In certain embodiments, the polynucleotides and compositions thereof can be used to reduce replication of feline herpes simplex virus 1 (FHV-1) in vivo and/or in vitro.08-13-2009
20090269846Inhibitors of tyrosine kinase receptor dimerization - The teachings relate to methods of identifying inhibitors of dimerization of tyrosine receptor kinases such as EGFR. The methods comprise providing, on a digital computer, a molecular model comprising a complex of extracellular dimerization domains of an RTK, docking a chemical databases to the molecular model, scoring the compounds comprised by the database, and identifying one or more high-scoring compounds. The methods further comprise testing a compound for RTK inhibitory activity in vitro, and testing a compound for specificity as an RTK inhibitor. Also disclosed are compounds selected by the described methods, and methods of treatment using the compounds. Two compounds (NSC11241 and NSC56452) are disclosed that inhibit EGF receptor kinase activation in a dose-dependent manner.10-29-2009
20120196363METHOD FOR MODULATING ACTIVITY OF T LYMPHOCYTES - The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.08-02-2012
20110020931PROLIFERATION PROMOTING AGENT FOR NEURAL STEM CELLS - A proliferation promoting agent for neural stem cells, which comprises a compound produced by 01-27-2011
20110020930Enrichment of Stem Cells from Adult Tissues - Subjecting a heterogeneous cell population (one with both stem cells and non-stem cells) to extreme stress selectively eliminated the non-stem cells and resulted in the enrichment of stem cells in the population. The stress can take many forms, including without limitation, cell toxins, high temperature, high salt, and low oxygen (hypoxic) conditions. The number of stem cells remaining after stress were increased, and showed increased expression of traditional stem cell markers. The stem cells were shown to be capable of proliferation and differentiation into multiple types of cells. This method allows purification of stem cells from adult heterogeneous cell populations on a large scale basis without requirement of expensive equipment, and without requiring the presence of cell surface markers. Stem cells produced by the above method can be used for clinical applications, including tissue engineering.01-27-2011
20090233358Method of Regulating A Phosphorylated Protein-Mediated Intracellular Signal Transduction Using An Antibody Specifically Binding To The Phosphorylated Protein - There are provided a method of regulating a phosphorylated protein-mediated intracellular signal transduction comprising intracellularly expressing an antibody that specifically binds to the phosphorylated protein and an expression system for intracellular expression of the antibody. The method and system are effectively used in the investigation, prevention, or treatment of diseases caused by a phosphorylated protein-mediated intracellular signal transduction, including prostate cancer, lung cancer and breast cancer, through regulation of a molecular interaction involving a phosphorylated residue of the phosphorylated protein.09-17-2009
20120115228OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR THE USE IN MODULATION OF MICRORNAS - Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activing in a cell.05-10-2012
20120231543NOVEL OPIOID ANTAGONISTS - Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.09-13-2012
20100068809Reproductive cell function preservation system - Compositions or extracts (2)(15)(24)(25)(16)(23)(31)(36)(41) obtained from the fruit (4) or leaves (26) of plants of the genus 03-18-2010
20130164846RNA MOLECULES AND USES THEREOF - The invention relates to a method of designing a short RNA molecule to increase the expression of a target gene in a cell through the down-regulation of a non-coding RNA transcript, said method comprising the steps of: a) obtaining the nucleotide sequence of the coding strand of the target gene, at least between 200 nucleotides upstream of the gene's transcription start site and 200 nucleotides downstream of the gene's transcription start site; b) determining the reverse complementary RNA sequence to the nucleotide sequence determined in step a); and c) designing a short RNA molecule which is the reverse complement or has at least 80% sequence identity with the reverse complement of a region of the sequence determined in step b); wherein said method does not include a step in which the existence of said non-coding RNA transcript is determined; as well as to such short RNA molecules and uses thereof.06-27-2013
20120238018Caged Ceramide-1-Phosphate Derivatives - The invention relates to novel caged ceramide 1-phosphate (C1P) and the method of using them for delivering C09-20-2012
20120238017NOVEL SIRNA STRUCTURE FOR MINIMIZING OFF-TARGET EFFECTS AND RELAXING SATURATION OF RNAI MACHINERY AND THE USE THEREOF - The present invention relates to a novel siRNA structure and the use thereof. More particularly, the invention relates to a double-stranded small interfering RNA molecule (siRNA molecule) comprising a 19-21 nucleotide (nt) antisense strand and a 15-19 nt sense strand having a sequence complementary to the antisense sequence, wherein the 5′ end of the antisense strand has a blunt end and the 3′ end of the antisense strand has an overhang, and to a method for silencing the expression of a target gene using the siRNA molecule.09-20-2012
20130164842BIOCOMPARTIPLE CONFEITO-LIKE GOLD NANOPARTICLES, METHOD FOR MAKING THE SAME, AND THEIR BIOMEDICAL APPLICATIONS - The present invention provides a method for producing gold nanoparticles using hydroxyl peroxide in an aqueous alkaline condition in the presence of a biocompatible protecting agent. The method of the invention does not involve toxic reagents and therefore are environmentally friendly. The gold nanoparticles thus produced can be used in biomedical applications including cancer therapy and drug delivery without purification.06-27-2013
20130164843Method and medicament for inhibiting the expression of a given gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.06-27-2013
20130164844COMPOUNDS AND METHODS FOR IMPROVING CELLULAR UPTAKE OF OLIGOMERIC COMPOUNDS - The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipeints for improved cellular uptake.06-27-2013
20120040459REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS - The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.02-16-2012
20090061514USE OF CYTOKINES AND MITOGENS TO INHIBIT GRAFT VERSUS HOST DISEASE - A method for inducing T cell tolerance in peripheral blood mononuclear cells (PBMCs) comprising adding a suppressive composition to said cells.03-05-2009
20110008890Self-Assembly of Peptide-Amphiphile Nanofibers Under Physiological Conditions - Peptide amphiphile compounds, compositions and methods for self-assembly or nanofibrous network formation under neutral or physiological conditions.01-13-2011
20090075378Somatic hypermutation systems - The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses.03-19-2009
20110111501COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA - An object of the present invention is to provide novel double-stranded RNA having an RNA interference effect, in which the cellular uptake and the resistance to enzymatic degradation are improved, without reducing the RNA interference effect.05-12-2011
20110300629TRAIL trimers, methods and uses therefor - Disclosed are TNF-related apoptosis-inducing ligand (TRAIL) trimers (TR3) and nucleic acids encoding covalently linked TRAIL trimers. A TRAIL trimer can have greater stability compared to native TRAIL, and can retain the native killing ability of TRAIL. Target specificity of a TR3 can be shown by blocking its activity with soluble death receptor 5 (DR5-Fc). Also disclosed are modified TRAIL trimers and nucleic acids encoding them. These modifications include additional functional domains, such as antibody fragments (scFvs). A TR3 comprising an additional functional domain can allow for cell-specific delivery of the TR3. In some configurations, a modification such as the addition of a functional domain can be stoichiometrically controlled. In some configurations, a modification can be inconsequential with regard to the bioactivity of TRAIL. In various embodiments, a TR3, including a modified TR3, can be a cancer-selective drug. In some configurations, a TR3 that comprises an additional biologically active moiety such as a functional domain of a protein can have fewer off-target toxicities compared to TRAIL alone. In some configurations, a TR3 that comprises an additional biologically active moiety such as a functional domain of a protein can have enhanced killing capacities compared to the moiety alone. In some aspects, TR3 activity can be targeted to an RBC membrane. The inventors disclose TR3-decorated RBCs that target cell killing in a model of pancreatic cancer.12-08-2011
20110003386IDENTIFICATION AND CHARACTERIZATION OF CANCER STEM CELLS AND METHODS OF USE - A subpopulation of cancer stem cells expressing elevated levels of uPAR have been identified among a population of cancer cells. Methods are provided for treating proliferative disorders such as cancer by administering one or more uPAR inhibitors. Methods are likewise provided for predicting the likelihood of recurrence of a cancer, preventing recurrence of a cancer, and identifying the likelihood of a cancer to respond to a particular cancer therapy.01-06-2011
20100068807INTERFERON-alpha REGULATOR - An object of the present invention is to elucidate the role of IKKα in TLR signaling and provide an agent and a method for controlling interferon-α. The present invention provides an agent for suppressing interferon-α production which comprises an agent for inhibiting IKKα.03-18-2010
20090068738COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES - The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).03-12-2009
20100159593TRANSFECTION REAGENTS - Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure:06-24-2010
20120288933SYNTHETIC MIMICS OF MIR-34 - Embodiments concern methods and compositions involving miR-34 mimics, including miR-34a and miR-34c mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34a sequence and a complementary passenger strand. In additional embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34c sequence and a complementary passenger strand.11-15-2012
20110136233NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF - The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing gene expression of PLK1 gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a PLK1 mRNA. Also provided are methods of decreasing expression of a PLK1 gene in a cell or in a subject to treat a PLK family member-related disease.06-09-2011
20110136232ANTI-PYK2 ANTIBODIES - This document provides methods and materials related to anti-Pyk2 antibodies. For example, anti-Pyk2 antibodies, methods for making anti-Pyk2 antibodies, and methods for using an anti-Pyk2 antibody to inhibit glioma cell migration are provided.06-09-2011
20110281353Composition and Method for Facilitating the Internalization of a Therapeutic Agent into a Cell - The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therape.11-17-2011
20110281354BISPECIFIC INTRACELLULAR DELIVERY VEHICLES - A composition for delivering an agent to a cell, comprising a bispecific affinity reagent and a pH-responsive, membrane destabilizing polymer. The bispecific affinity reagent may include a first affinity reagent covalently linked to a second affinity reagent, wherein the first affinity reagent binds to a molecule on the surface of a cell, and the second affinity reagent binds to an intracellular target.11-17-2011
20110287535Histone Deacetylase Inhibitors - Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.11-24-2011
20110287537NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES - Disclosed herein are methods of treating neurodegenerative diseases comprising administering to the subject a compound having the structure:11-24-2011
20110287536SIMPLIFIED METHOD FOR PARTIAL GENETIC AND EPIGENETIC REPROGRAMMING OF CELLS - A method of partial, rapid and direct genetic and epigenetic reprogramming of biological cells without returning to the embryonic state can partially reprogram a cell to be treated to specifically modify the biological age of said cell to be treated without causing functional de-differentiation of said cell to be treated, said cell to be treated always remaining as a specialized functional cell that is immunologically autologous to the donor tissue from which said cell to be treated is derived, and for which the phenotype is preserved and/or rejuvenated.11-24-2011
20110294212Methods of Screening Molecular Libraries and Active Molecules Identified Thereby - The present invention provides a peptide having 2 to 10 amino acids or a derivative thereof which is able to restore wild type function of human p53, for use in therapy; and a method of screening a library of molecules for the ability of members of that library to restore or modify the function of a target protein in an intra-cellular environment, which method comprises introducing the library into host cells which have a reporter system which allows the identification of those cells in which the function of the target protein has been restored or modified.12-01-2011
201102942132'-ARABINO-FLUOROOLIGONUCLEOTIDE N3'-P5' PHOSPHORAMIDATES: THEIR SYNTHESIS AND USE - Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2′-arabino-fluoronucleoside and an internucleoside 3′-NH—P(═O)(OR)—O-5′ linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2′-aribino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.12-01-2011
20090275134COMPOSITIONS OF ACTIVE WNT PROTEIN - Compositions of purified biologically active Wnt proteins are provided. Wnt proteins are found to be hydrophobic and post-translationally modified by addition of a lipid moiety at a conserved cysteine residue. Methods for isolation of Wnt utilize detergents that maintain the solubility of the modified protein.11-05-2009
20090221071Polyurea Systems, Processes for Preparing the Same and Use Thereof for Postoperative Adhesion Barriers - Polyurea systems comprising: (a) an amino-functional aspartic ester of the general formula (I)09-03-2009
20080311659RIBONUCLEIC ACID INTERFERENCE MOLECULES OF ORYZA SATIVA - Sequences of ribonucleic acid interference molecules are provided. For example, in one aspect, at least one nucleic acid molecule comprising at least one of one or more precursor sequences having SEQ_ID NO: 1 through SEQ_ID NO: 11,928 and one or more corresponding mature sequences having SEQ_ID NO: 11,929 through SEQ_ID NO: 24,555 is provided. Techniques are also provided for regulating gene expression.12-18-2008
20080311658COMBINED HAIRPIN-ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION - A nucleotide construct comprising a nucleotide sequence that forms a stem and a loop, wherein the loop comprises a nucleotide sequence that modulates expression of a target, wherein the stem comprises a nucleotide sequence that modulates expression of a target, and wherein the target modulated by the nucleotide sequence in the loop and the target modulated by the nucleotide sequence in the stem may be the same or different. Vectors, methods of regulating target expression, methods of providing a cell, and methods of treating conditions comprising the nucleotide sequence are also disclosed.12-18-2008
20090203131Polyamides for nucleic acid delivery - The present invention describes reagents and methods for using concatermized double-stranded oligonucleotide molecules (CODN) for transcription factor decoys. In one embodiment, the concatemers consist of a variable number of end-to-end copies of a short dsDNA containing a sequence or sequences that act as transcription factor decoys.08-13-2009
20100197018USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES - Provided is a method of enhancing the activity of lysosomal enzymes using substrates that are derivatives of natural substrates as pharmacological chaperones.08-05-2010
20090148944CELL-TYPE SPECIFIC APTAMER-siRNA DELIVERY SYSTEM FOR HIV-1 THERAPY - The present invention relates to compositions and methods for delivery of siRNA to specific cells or tissue. More particularly, the present invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer.06-11-2009
20090148942HUMANIZED ANTI-CD70 BINDING AGENTS AND USES THEREOF - Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.06-11-2009
20090148943AGENT FOR ENHANCING THE PRODUCTION OF CYTOKINES AND/OR CHEMOKINES - The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.06-11-2009
20090233359POLYMERS AND COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS TO INTRACELLULAR TARGETS - A complex includes a nucleic acid and a cationic polymer with at least one side chain coupled to the nucleic acid. The at least one side chain including an acid degradable amine-bearing ketal or acetal linkage.09-17-2009
20100267138COMPOSITIONS AND METHODS COMPRISING A LIGAND OF CHEMERINR - The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screeing assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.10-21-2010
20100120146ACTIVATOR OF SIGNAL TRANSDUCTION PATHWAY - The present invention is directed to providing the activator of the integrin signaling in neural stem cells or neural progenitors and the method for using the same. The activator of the integrin signaling comprises galectin-1 and can be used as a regulator that regulates maintenance, survival, or differentiation of a neural stem cells or a neural progenitor.05-13-2010
20100120147ANTAGONIST OF LIGANDS AND USES THEREOF - The invention provides multivalent ligand binging agents (traps) for members of the TGF-β superfamily and polypeptide linkers and methods for making and using such constructs. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-β superfamily, said agent comprising the general structure I: (-linker1)05-13-2010
20090081789Activation of nuclear factor kappa B - The present invention describes a method for targeting a tumor cell comprising contacting the tumor cell with a composition comprising a macrophage and a factor that upregulates nuclear factor-kappa B (NFκB) activity.03-26-2009
20120107933ANTI-MESOTHELIN ANTIBODIES - The present invention provides monoclonal anti-mesothelin antibodies and antibody fragments and methods for their use. The antibodies can be completely human.05-03-2012
20120107932PRRS-VIRUS RECEPTOR AND ITS INHIBITOR - This invention relates to a new cell receptor of the PRRS virus, i.e. as non-muscle myosin II-A (NMHC II-A)and its inhibitor blebbistatin, which can be used as a drug for suppressing PRRS virus infection of cells. The invention provides a method of utilizing purified NMHC II-A protein, artificially synthesized polypeptides and blebbistatin to prevent PRRS viruses from infecting cells. It also offers the antibodies generated by NMHC II-A protein and polypeptides. The purified NMHC II-A protein or artificially synthesized polypeptides and blebbistatin as well as anti-NMHC II-A protein and anti-polypeptide antibodies all have inhibitory effects on cell infection from the PRRS virus, and can be developed into drugs for preventing and treating infections of the PRRS virus.05-03-2012
20100081197In vivo modulation of neuronal transport - A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells allows visualization of an active synapse. Also, a method for screening molecules capable of modulating synapse activity is provided. A kit useful for the early diagnosis of neurodegenerative disease comprises a biomarker comprising at least fragment C of tetanus toxin and a reporter protein.04-01-2010
20090093057Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders - The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.04-09-2009
20090162933EPHA2 AND HYPERPROLIFERATIVE CELL DISORDERS - The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation, in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low K06-25-2009
20090142832Indoles, Derivatives, and Analogs Thereof and Uses Therefor - Indole derivatives and analog compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat a cancer.06-04-2009
20080241922Use of Biocistronic DNA Constructs for Identifying Compounds that Inhibit IRES-Dependent Translation - The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.10-02-2008
20080206867Fc variants with optimized Fc receptor binding properties - The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.08-28-2008
20080206866Reagency and Method for Preventing Time-Dependent Expression in Biological Cells - The present invention relates to a reagent for prevention of time-dependent, induced expression in biological cells in a sample. It likewise relates to a method for this purpose and also to cell preparations treated in this manner, the reagent for prevention of time-dependence induced expression in biological cells in a sample ex vivo containing a formaldehyde donor.08-28-2008
20090275135MAMMALIAN CYTOKINES; RECEPTORS; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.11-05-2009
20090275133ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION - Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.11-05-2009
20090291497siRNA targeting transducin (beta)-like 3 (TBL3) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TBL3.11-26-2009
20110201112Vault Complexes for Facilitating Biomolecule Delivery - The invention relates to compositions of vault complexes containing recombinant membrane lytic proteins, such as an adenovirus protein VI lytic domain, and methods of using the vault complexes to facilitate delivery and entry of a biomolecule into a cell or subject.08-18-2011
20090170195CURCUMIN-HYALURONAN COMPOUNDS - A dissociable complex is disclosed. The dissociable complex includes at least one molecule of curcumin, at least one molecule of hyaluronic acid, and at least one linker molecule, wherein a first portion of the linker molecule is bonded to the curcumin and a second portion of the linker molecule is bonded to the hyaluronic acid.07-02-2009
200901370413-HYDROXYISOTHIAZOLE-4-CARBOXAMIDINE DERIVATIVES AS CHK2 INHIBITORS - This invention provides compounds of Formula I05-28-2009
20110269230METHODS AND COMPOSITIONS FOR MAINTAINING GENOMIC STABILITY IN CULTURED STEM CELLS - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies.11-03-2011
20100279406Alteration of tumor growth using zinc finger proteins - The present invention provides methods for altering tumor growth using zinc finger proteins.11-04-2010
20120288935"Click" Nanoparticle Conjugates - Modified nanoparticles are disclosed. More specifically, nanoparticles modified with an agent through a triazole linkage are disclosed. Also disclosed are methods of preparing modified nanoparticles and methods of using these modified nanoparticles.11-15-2012
20120288934DEVICE AND METHOD FOR TREATING LIVING CELLS BY MEANS OF A PLASMA - A device for treating living cells by plasmaporation contains, in addition to devices for generating plasma and generating a field, devices for mixing and transporting active substances, predominantly in the form of nano and microparticles, for affecting the metabolism of the cells.11-15-2012
20080241923Humanized Anti-CCR2 Antibodies and Methods of Use Therefor - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.10-02-2008
20090170196CANCER TREATMENT USING C-TYPE NATRIURETIC PEPTIDE - The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.07-02-2009
20080274544Promotor for Introducing Extracellular Substance into Mammalian Ovum and Introduction Method - The present invention provides a method, upon introducing an extracellular substance, such as sperm, a cell nucleus, a nucleic acid, and a protein, into a mammalian oocyte, for introducing the extracellular substance into a mammalian oocyte, which is safe for the mammalian oocyte, enables efficient introduction, and is technically easy. By treating the mammalian oocyte with a tubulin-polymerization inhibitor such as vinblastine, membrane fusion between the oocyte and the sperm is promoted, and the sperm and the oocyte are fused without making a hole in the oolemma and fertilization can be achieved. The method of the present invention can be applied not only to the case of introducing sperm into a mammalian oocyte, but also to the case of introducing an extracellular substance, such as a cell nucleus, a nucleic acid, and a protein, into a mammalian oocyte.11-06-2008
20080280358Synthetic Peptides that Cause F-Actin Bundling and Block Actin Depolymerization - Synthetic peptides derived from sucrose synthase, and having homology to actin and actin-related proteins, sharing a common motif, useful for causing acting bundling and preventing actin depolymerization. Peptides exhibiting the common motif are described, as well as specific synthetic peptides which caused bundled actin and inhibit actin depolymerization. These peptides can be useful for treating a subject suffering from a disease characterized by cells having neoplastic growth, for anti-cancer therapeutics, delivered to subjects solely, or concomitantly or sequentially with other known cancer therapeutics. These peptides can also be used for stabilizing microfilaments in living cells and inhibiting growth of cells.11-13-2008
20080305543RNA interference pathway genes as tools for targeted genetic interference - Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.12-11-2008
20080233646Human DR4 antibodies and uses thereof - Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.09-25-2008
20080233644Chimeric Transcription Factor Decoy Oligonucleotides - A method for the treatment of the brain cancer glioblastoma multiforme (GBM) is provided. The method involves decreasing the expression of Matrix Metalloproteinase-1 (MMP-1) expression by providing transcription factor decoy nucleotides that mimic single nucleotide polymorphisms responsible for MMP-1 overexpression.09-25-2008
20090042291Optimized Fc variants - The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.02-12-2009
20090029468ZINC FINGER BINDING DOMAINS FOR CNN - Polypeptides that contain zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula CNN are provided. Compositions containing a plurality of polypeptides, polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides, compositions and polynucleotide's are also provided.01-29-2009
20090298175Steroidal Ligands and Their Use in Gene Switch Modulation - The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.12-03-2009
20090298173Method of preparing cell for bone tissue formation and application of cell for bone tissue formation - It is intended to provide a method of efficiently and stably preparing a cell having a bone tissue formation ability by a simple operation. Further, it is intended to provide a method of preparing a composition for bone tissue formation with high safety and an excellent therapeutic effect by a simple operation. The cell for bone tissue formation is obtained by (1) culturing bone marrow after isolating it from a living body, diluting it at a predetermined dilution ratio and inoculating it to a culture vessel, (2) culturing the remaining adhesive cells after removing floating components, (3) inducing differentiation of proliferated cells to bone cells and (4) recovering the cells. The thus obtained cells, a thrombin solution, platelet-rich plasma and air are mixed at a predetermined mixing ratio (based on volume) in the presence of calcium ions and the mixture is gelled, whereby a gelled composition is obtained.12-03-2009
20100015707SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION - Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.01-21-2010
20100151573Compositions and methods for delivery of molecules to selectin-ligand-expressing and selectin-expressing cells - The present invention is directed to methods for delivery of payload molecules to selected cells. The method comprises payload carrying delivery vehicles tagged with selectin or selectin-ligands. The payload carrying delivery vehicles are immobilized on flow surfaces and payload is delivered to targeted cells during rolling. The invention is also directed to compositions and devices for carrying out the method.06-17-2010
20090325292Functional polyglycolide nanoparticles derived from unimolecular micelles - Poly(glycolide) polymers are disclosed. The polymers generally include a glycolide-based polymer backbone that includes one or more functional groups such as alkynyl groups, hydrophilic organic triazole groups, hydrophobic organic triazole groups (also including amphiphilic organic triazole groups), di-triazole organic crosslinking groups, and triazole-substituted drug derivatives. The alkynyl groups provide reactive sites for further functionalization of the polymer, for example by reaction with azide derivatives. The polymers can further encapsulate a drug for delivery to a patient (i.e., as compared to drug derivatives that are covalently attached to the polymer). The polymers can be in the form of thermodynamically stable unimolecular micelles or crosslinked nanoparticles. The polymer compositions are completely biodegradable and hold great potential for use in biomedical applications.12-31-2009
20090325291METHOD OF PREPARING siRNAs FOR SELECTIVE INHIBITION OF TARGET mRNA ISOTYPES - A method of preparing siRNAs for selective inhibition of target mRNA isotypes comprises: dividing target mRNA isotypes intended to inhibit the expression thereof and non-target mRNA isotypes from the mRNA isotypes of a gene; allotting a common location information region (A) of exons on genome DNA corresponding to the target mRNA isotypes; allotting a location information region (B) present specifically in exons of genome DNA corresponding to target mRNAs by excluding the location information region of exons on genome DNA corresponding to non-target mRNA from the location information region (A); determining base sequences in the target mRNAs corresponding to the location information region (B); and obtaining siRNA sequences for inhibiting the determined base sequences specifically. The method of the present invention can be used to prepare siRNAs for selective inhibition of specific target mRNA isotypes in a gene having several isotypes by alternative splicing, and enables siRNA design for all the genes in genome, making good tool for functional genomics study.12-31-2009
20090081787AGENT FOR PROMOTING HEPATIC CELL REPLICATION AND AGENT FOR IMPROVING INSULIN RESISTANCE - The present invention aims at providing a medicament and a method for promoting replication of hepatocytes and a medicament and a method for ameliorating insulin resistance. An effective amount of a neutralizing agent for CXCL10 belonging to a subfamily of chemokines which are heparin-binding proteins is administered to the hepatocytes to promote the replication of the hepatocytes. As the neutralizing agent for CXCL10, a factor which is specifically bound to CXCL10 and inhibits an activity of CXCL10 or a factor which inhibits CXCL10 expression is suitably used. By administering the neutralizing agent to impaired hepatic tissue, it is possible to restore and regenerate the hepatic tissue. Meanwhile, by administering an effective amount of the neutralizing agent for CXCL10 to the hepatocytes, the insulin resistance in type II diabetes and metabolic syndrome is ameliorated.03-26-2009
20080233647NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.09-25-2008
20100267139OSTEOPONTIN NANOPARTICLE SYSTEM FOR DRUG DELIVERY - The present invention relates to nanoparticles comprising osteopontin and a polymer carrier, preferably a cationic carrier. Preferably, the cationic carrier is chitosan. Osteopontin and/or the cationic carrier may have bioactivity and/or the nanoparticle may comprise an additional component with bioactivity. Such additional bioactive component may e.g. be a siRNA. The nanoparticles of the invention may be used for treatment of bone diseases or inflammatory diseases.10-21-2010
20090081790Polynucleotide for Target Gene - The present invention provides a single strand polynucleotide sequence comprising a target gene, a complementary strand nucleic acid sequence, and a component sequence.03-26-2009
20090081786Peptide sequences for modulation of protein kinase C - Peptides found within an annexin protein can be used to modulate the activity of a protein kinase C are described. More particularly, peptides within annexin I, V, and VI, as well as variants and conservatively modified variants thereof, are described, and use of these peptides to regulate cellular responses mediated by β-protein kinase C, δ-protein kinase C, and α-protein kinase C, respectively, are described.03-26-2009
20090081788Nucleotide sequence encoding the enzyme I-SceI and the uses thereof - An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.03-26-2009
20110143434DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS - Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.06-16-2011
20090053808COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF ANTI-APOPTOPIC GENES - The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.02-26-2009
20110229966Nanoparticle-Based Gene Delivery Systems - The present invention provides a gene delivery system containing nanoparticles. In more detail, the present invention provides a gene delivery system containing (a) a nanomaterial; (b) an oligonucleotide as an universal binding partner covalently linked to the surface of the nanomaterial; and (c) a cargo comprising (i) a complementary oligonucleotide containing a nucleotide sequence complementary to the universal binding partner as a binding counter-partner, and (ii) an inhibitory molecule having a nucleotide sequence complementary to a target gene of interest to be inhibited or an inducible molecule having a nucleotide sequence of a target gene of interest to be expressed. The present invention is a gene delivery system capable of feasibly deliver aptamer, siRNA, shRNA, miRNA, ribozyme, DNAzyme, PNA or gene as well as antisense oligonucleotide into the cells. In addition, the present invention is more efficient than the commercially available gene transfer reagent in respect to the degree of knockdown of target protein expression.09-22-2011
20090191630Dual Inhibitors of HIV-1 GP-120 Interactions - Compounds, which inhibit the binding of gp120 to CD4 as well as 17b and methods for their use in inhibiting the HIV fusion process, are provided.07-30-2009
20090191629MAMMALIAN CHEMOKINE REAGENTS - Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods of using said reagents and diagnostic kits are also provided.07-30-2009
20110223664MATERIALS AND METHODS OF INTRODUCING GENETIC MATERIAL INTO LIVING CELLS - The present invention generally relates to introducing genetic material to living cells. In some embodiments, the present invention relates to compositions of matter for targeted delivery of nucleic acids to cells. In other embodiments, the present invention relates to methods of targeted delivery of nucleic acids to cells. In still other embodiments, the present invention relates to polymers that contain at least one amino acid in their backbone. In yet other embodiments, the present invention relates to polymers that contain at least one amino acid in their backbone thereby resulting in biodegradability, and in some embodiments, controlled biodegradability.09-15-2011
20090053807Insulin and IGF-1 Receptor Agonists and Antagonists - Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.02-26-2009
20090203137COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION - The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.08-13-2009
20100248365GANGLIOSIDE BIOSYNTHESIS MODULATORS - Provided herein are ganglioside synthesis inhibitors, including modulators of ganglioside glycosylation.09-30-2010
20120142098Fc receptor-binding polypeptides with modified effector functions - Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.06-07-2012
20100248364SENSE OLOGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME - The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.09-30-2010
20090215173PKD Ligands and Polynucleotides Encoding PKD Ligands - The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate protein kinase D (PKD) activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to cellular localization signals, epitope tags and/or reporters. The invention also includes polynucleotides encoding the ligands and polyligands.08-27-2009
20080261303Method and medicament for inhibiting the expression of a given gene - The present invention relates to the specific inhibition of expression of a target gene in mammals using a short double stranded RNA. The dsRNA is less than 49 nucleotides in length and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases, for example, cancer, viral diseases or neurodegenerative diseases.10-23-2008
20120196364INHIBITION OF MIGRATION AND INDUCTION OF CELL DEATH BY THE TYPE II COLLAGEN AMINO PROPEPTIDES - The present invention provides combinations and methods for inducing cell death, inhibiting angiogenesis, and inhibiting cell migration. In particular, the present invention provides methods for inducing cell death in a cell expressing an αvβ3 and/or an αvβ5 integrin.08-02-2012
20090258422OPTICALLY DETECTABLE ORGANOPHOSPHONATES - The invention relates to compounds having general formula I10-15-2009
20110143435POLYMERIC CARRIER - Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g. oligonucleotides) and/or other therapeutic agents into a living cell.06-16-2011
20100173412Eukaryotic Layered Vector Initiation Systems - The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems07-08-2010
20100015708RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF - The present disclosure provides a ribonucleic acid comprising a double-stranded region having at least one base pair comprising a 5-methyluridine base paired with a 2,6-diaminopurine and methods for preparing the same. Also provided are methods for treating or preventing a disease or disorder by inducing RNAi.01-21-2010
20120142099NOVEL BAK BINDING PROTEIN, DNA ENCODING THE PROTEIN, AND METHODS OF USE THEREOF - The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.06-07-2012
20100184215MODIFIED THIOREDOXIN - The present invention relates to a human modified thioredoxin composed of any of the following polypeptides: (a) a polypeptide modified by alteration or chemical modification of a cysteine residue at position 35 with another amino acid in an amino acid sequence of SEQ ID NO:2; and (b) a polypeptide having an amino acid sequence having one or more substituted, deleted, inserted or added amino acids in positions except for positions 32 and 35, preferably positions 32 to 35 in the amino acid sequence of SEQ ID NO:2, and having an apoptosis-inducing activity.07-22-2010
20100173413PYRIDINE COMPOUNDS - This invention features compounds of formula (I):07-08-2010
20080213889INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY - The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.09-04-2008
20100227403rbLIF PROTEIN FOR USE IN EMBRYONIC STEM CELL CULTURES - Provided herein methods of maintaining an embryonic stem cell culture in an undifferentiated state, wherein the method includes culturing an embryonic stem cell on a rabbit feeder cell layer, wherein the rabbit feeder layer expresses a leukemia inhibitory factor (LIF) protein. Also provided are methods of maintaining an embryonic stem cell culture in an undifferentiated state, wherein the method includes culturing an embryonic stem cell in a culture medium comprising rabbit leukemia inhibitory factor (rbLIF) protein. Also provided are polynucleotide and amino acid sequences of a rabbit leukemia inhibitory factor protein (rbLIF).09-09-2010
20100227402Cell Surface Coating with Hyaluronic Acid Oligomer Derivative - A method of localising reproduction assisting hyaluronic acid to reproductive cells surfaces by covalently linking it to lipids is disclosed.09-09-2010
20100159592Emulsion compositions - An emulsion is useful in allowing a wide variety of gene products to be expressed via eukaryotic in vitro expression. The emulsion comprises a silicone based surfactant, a hydrophobic phase and a hydrophilic phase; wherein the hydrophilic phase comprises a plurality of compartments containing a functional in vitro eukaryotic expression system.06-24-2010
20100159594SINGLE CHAIN TRIMERS AND USES THEREFOR - Single chain trimer (SCT) molecules are disclosed, comprising an MHC antigen peptide sequence, a β06-24-2010
20100151572ANTI-TUMORAL COMPOSITIONS METHODS - Described are methods and compositions for inhibiting undesired cells by expression of one or more exogenous enzymes in the cells and administration of a prodrug which is a substrate for at least one of the enzymes to produce a cytotoxic compound. Inventive methods and compositions are active to inhibit cells expressing the exogenous enzymes as well as bystander cells. Tumor cells are a particular target for inhibition using methods and compositions detailed according to the present invention. Provided are methods and compositions for improved anti-tumoral effects by overexpression of adenine phosphoribosyltransferase (APRT) to produce cytotoxins which inhibit the cells overexpressing the APRT as well as bystander cells. Overexpression of APRT in conjunction with expression of 06-17-2010
20100240129Transfer of Molecules - The invention relates to liposomes, particularly, but not exclusively, to liposomes for introducing a molecule into a cell, and to processes for making and using liposomes.09-23-2010
20100240128Modified Gene Silencing - This invention relates to methods of controlling gene expression or gene suppression in eukaryotic cells. One aspect of this invention includes modifying the degree of silencing of a target gene by use of a modified suppression element. Another aspect includes providing a eukaryotic cell having a desired phenotype resulting from transcription in the eukaryotic cell of a modified suppression element. Also provided are transgenic eukaryotic cells, transgenic plant cells, plants, and seeds containing modified suppression elements, and useful derivatives of such transgenic plant cells, plants, or seeds, such as food or feed products.09-23-2010
20130217124MODIFIED SILICA SHELL PARTICLES, AND METHODS OF MAKING AND USING THE SAME - Provided herein are silica shell particles modified on their surface with biomolecules, methods of making these particles, and methods of using these particles, e.g., in transfection methods, methods of inhibiting gene expression, and methods of delivering a therapeutic.08-22-2013
20120129255FUNCTIONALIZATION OF SILK MATERIAL BY AVIDIN-BIOTIN INTERACTION - The present invention provides for compositions and methods of linking silk fibroin to active agents through the specific interaction between avidin and biotin, providing for functionalization of silk-based protein biomaterials. An avidin- or biotin-modified silk is a biomaterial platform for functionalization with a variety of correspondingly linked active agents, such as antibodies and growth factors. A variety of functionalized silk materials, such as silk hydrogel, silk micro/nanoparticles and silk films, can be prepared by the methods of the present invention. The functionalization strategies of the present invention are relatively easy, fast and feasible, and are thus useful in many biomedical applications.05-24-2012
20100136687Methods for Enhanced Propagation of Cells - The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).06-03-2010
20090075379MODULATION OF HOMOLOGOUS RECOMBINATION WITH SINGLE STRANDED DNA BINDING PROTEINS - In one aspect of the invention, single stranded DNA binding proteins (SSB) may be used to modulate homologous recombination in mitosis or meiosis. method are provided for modulating homologous recombination comprising transforming a cell with a nucleic acid encoding a single stranded DNA binding protein; and, allowing the cell to undergo mitosis or meiosis. Similarly, methods are provided for modulating homologous recombination comprising transforming a cell with an inhibitor of expression of a dingle stranded DNA binding protein, such as an antisense or co-suppressive nucleic acid; and, allowing the cell to undergo mitosis or meiosis.03-19-2009
20120142100HEAT SHOCK RNA FROM VARIOUS SPECIES AND ITS USE IN ACTIVATION OF HEAT SHOCK TRANSCRIPTION FACTOR, IN TREATMENT OF VARIOUS DISEASES IN ANIMALS AND IN GENERATION OF STRESS-RESISTANT PLANTS - The present invention provides a novel RNA, designated herein as the “HSR1” (Heat Shock RNA), and its use together with translation elongation factor eEF1A in activation of heat shock transcription factor HSF. The invention further provides the use of HSR1 for generation of novel therapeutics for the treatment of various diseases in animals and for generation of stress-resistant plants.06-07-2012
20120142101OLIGONUCLEOTIDE END CAPS - Modified nucleic acids are described herein, including pharmaceutical compositions comprising the modified nucleic acids, and methods of using the modified nucleic acids.06-07-2012
20110027884COMBINATION OF INSULIN AND ASCORBATE TO ENHANCE WOUND HEALING - Provided is a method of stimulating collagen synthesis and proteoglycan (lumican and keratocan) accumulation. Collagenase isolated keratocytes were cultured with or without insulin with or without ascorbate. Insulin stimulates the synthesis of collagen but does not affect the accumulation of lumican and keratocan. Insulin plus ascorbate, however, stimulates the synthesis of collagen and increased the accumulation of these proteoglycans. The accumulation of PGDS, a KSPG that does not interact with collagen, is not affected by ascorbate. Only the collagen made in the presence of ascorbate was pepsin resistant. EDB overrode the effects of ascorbate on pepsin resistance and proteoglycan accumulation.02-03-2011
20110027883RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a 02-03-2011
20110027882Methods and Compositions for Treating Neurological Disease - This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases.02-03-2011
20100221832ADSORBENT FOR LYMPHOCYTE PROLIFERATION INHIBITOR AND TREATING METHOD - The invention has for its object to provide a porous material capable of relieving the lymphocyte proliferation inhibition in lymphocyte culture and improving the proliferative nature of lymphocytes as well as a method for proliferating lymphocytes and a method for producing lymphocytes each of which utilizes such porous material.09-02-2010
20080280359Oligoribonucleotide Inhibiting Growth of Tumor Cells and Method Therefor - The present inventors found that NEK2 kinase (accession number NM_002497) is expressed specifically in tumor cells such as bile duct carcinoma cells and that repression of the expression of NEK2 kinase by the use of RNA interference method led to inhibition of the growth of the tumor cells.11-13-2008
20130137173NUCLEOTIDE-SPECIFIC RECOGNITION SEQUENCES FOR DESIGNER TAL EFFECTORS - The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.05-30-2013
20100297760PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF PROSTATE CANCER - The present invention is directed to pharmaceutical compositions and methods for treatment of prostate cancer in a subject. The pharmaceutical composition includes a therapeutically effective amount of compound mahanine, or derivatives, or analogues, or pharmaceutically acceptable salt thereof. The present invention is further directed to a method of isolating compound mahanine from 11-25-2010
20110236974COMPOSITIONS AND METHODS FOR MAKING AND USING LAMININ NANOFIBERS - The present invention provides methodologies and parameters for fabrication of the hybrid biomaterial by blending pure laminin or complex extracts of tissues containing laminin with biopolymers such as polycaprolactone (PCL), polylactic/polyglycolic acid copolymer (PLGA) or Polydioxanone (PDO) in fluoroalcohols (HFP, TFA), fabrication of substrates and scaffolds and devices from the hybrid biomaterial in forms such as films, nanofibers by electrospinning or microspheres, and the biological or biomedical use of the material or devices derived from it.09-29-2011
20100311166METHOD OF IMPROVING CELL PROLIFERATION OF PANCREATIC PROGENITOR CELLS IN A PANCREATIC CELL CULTURE - The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.12-09-2010
20130143320METHODS AND COMPOSITIONS FOR MANIPULATING THE GUIDED NAVIGATION OF ENDOTHELIAL TUBES DURING ANGIOGENESIS - Methods and compositions for manipulating the directed navigation of physiological tracking tubular structures are provided. A novel cell-bound receptor, roundabout-4 (Robo-4), is described. The Robo-4 receptor shows sequence and structural similarity to members of the roundabout family of receptors. Also, the Robo-4 receptor binds Slit ligand, a known receptor of the roundabout receptors. Polynucleotides and polypeptides of the Robo-4 receptor are described.06-06-2013
20090068736Mutant proline-and-arginine rich peptides and methods for using the same - The present invention relates to mutant proline-and-arginine rich (PR) peptides with defined structural characteristics for use in inhibiting mammalian 20S proteasome activity and modulating expression of genes regulating the NF-κB pathway. Mutant PR peptides of the present invention differ from wild-type PR peptides by having at least one to three amino acid substitutions, wherein at least one of the amino acid residues at position one, two or three of the mutant PR peptide is positively charged.03-12-2009
20090035853TSG101-GAG INTERACTION AND USE THEREOF - Isolated protein complexes are provided comprising Tsg101 and HIV GAG or GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAG or GAGp6 interaction within the protein complexes.02-05-2009
20090233357Targeted Delivery of Compounds Using Multimerization Technology - There is disclosed herein subunits and multimers of subunits suitable for use in inducing the transport of one or more cargo substances into a cell and in some instances across a cell. The subunits may have a targeting domain such a antibody or antibody fragment, a multimerization domain, such as a verotoxin B-subunit mutant scaffold, and a cargo molecule such as a drug or imaging agent, which may be directly linked to the subunit or may be packaged in a liposome, nanoparticle, or the like. In some instances the targeting domain may have affinity for a blood-brain barrier antigen and may be capable of inducing cell mediated transcytosis to facilitate delivery of the cargo molecule across the blood-brain barrier. In some instances the targeting region may have affinity for a cancer antigen and may be capable of inducing cell-mediated endocytosis.09-17-2009
20090035852Stable Atomic Quantum Clusters, Production Method Thereof and Use of Same - Stable atomic quantum clusters, AQCs, characterized by being composed of at least 500 metal atoms, its production process characterized by having a kinetic control and by maintaining a low concentration of reagents in the reaction medium, as well as the uses of these clusters as sensors (fluorescent, magnetic or chemical), electrocatalysts and as cytostatics and/or cytotoxics.02-05-2009
20110033929USES OF ANTIBODIES TO MAMMALIAN DC LANGERHANS CELL ANTIGEN - The present invention relates to purified mammalian DC cell surface protein, designated Langerin, nucleic acids encoding Langerin, and antibodies which specifically bind Langerin.02-10-2011
20100178699MULTI-CHAIN LIPOPHILIC POLYAMINES - There are provided multi-chain lipophilic polyamine compounds and derivatives thereof, pharmaceutical formulations comprising the same, method of making and using said compounds or formulations.07-15-2010
20080241924Antibody-Mediated Induction of Tumor Cell Death - This invention provides methods and reagents for inducing cell death in tumor cells. The invention provides said reagents relating to inducing tumor cell death that are antibodies to a specific target, L1CAM, and methods for using said antibodies for inducing cell death. Pharmaceutical compositions of the L1CAM antibodies for use in the practice of the methods of the invention are also disclosed.10-02-2008
20110033930METHOD FOR OBTAINING NGN3-EXPRESSING CELLS AND INSULIN PRODUCING-BETA CELLS - The present invention relates to a method for obtaining Ngn3-expressing cells and insulin producing-beta cells by contacting a Pdx1-expressing pancreas explant with an amount of at least one histone deacetylase inhibitor (HDACi). The inventive methods have the advantage of being simple and quick, and of providing large amounts of Ngn3-expressing cells and insulin producing-beta cells, that are useful therapeutic tools. The invention also relates to a pharmaceutical composition for the treatment of diabetes which comprises an amount of at least one HDACi.02-10-2011
20100159591METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE - The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.06-24-2010
20100047910SUPRAMOLECULAR COMPLEXES AS PHOTOACTIVATED DNA CLEAVAGE AGENTS - The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging π-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.02-25-2010
20100047909NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease.02-25-2010
20110244568RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE - The present invention relates to a 10-06-2011
20110244570VOLUME EXCLUSION AGENT TO ENHANCE FORMATION OF EXTRACELLULAR MATRIX - A method of enhancing the formation of extracellular matrix in culture. Cells in culture secrete most of the collagen into the media as unprocessed procollagen, i.e., the cells do not convert procollagen to collagen. In contrast, normal extracellular matrix deposition involves procollagen processing to collagen, fibril assembly and deposition into the cell layer to form a collagenous extracellular matrix. The addition of certain growth factors and the addition of a thin layer of a certain volume exclusion agent on top of the cells dramatically enhances the conversion of procollagen to collagen and will increase the amount of collagen and extracellular matrix associated with the cells. This invention advances bioengineering of connective tissues for medical applications that require an extensive and functional extracellular matrix with high tensile strength such as those in the cornea stroma, skin, tendons, ligaments, articular cartilage and the intervertebral disks.10-06-2011
20110244569METHOD OF INDUCING PROLIFERATION AND/OR DIFFERENTIATION OF NEURAL PRECURSOR CELLS BY INTRODUCING PROLACTIN OR WNT3A TO ACTIVATE LATENT NEURAL PRECURSOR CELLS - A method of inducing proliferation and/or differentiation of a hippocampal cell population activating a latent neural precursor cell, enriching a cell population for neural precursor cells and treating neurodegenerative diseases and/or repopulating a damaged hippocampus by introducing prolactin or Wnt3a so as to activate a latent neural precursor cell population.10-06-2011
20110129921TARGETED POLYMER BIOCONJUGATES - Polymer bioconjugate having a RNAi agent covalently coupled to the alpha or omega end of a pH-dependent membrane-destabilizing polymer.06-02-2011
20110086425DELIVERY OF siRNAs - The present invention provides siRNA delivery methods use in vivo or in vitro. The delivery methods include conjugation with delivery peptides and mixing with dendrimers.04-14-2011
20090311783INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ANTAGONISTS - The present invention relates to IGF-I variants that bind to the Insulin-like Growth Factor Receptor I (IGF-IR) but do not initiate signal transduction and the subsequent metabolic, growth and anti-apoptotic activities associated with this molecule and the progression of cancer. These novel variants act to block the binding of the cognate ligands but do not bind to the insulin receptor.12-17-2009
20100009443Laboratory Apparatus for a Controlled Environment - A controlled environment system for use in In-Vitro Fertilization (IVF) or other biological procedures and a method for conducting such a biological procedure. The system includes a main chamber, one or more manipulator devices for manipulating items in the interior of the chamber, a microscopy viewing system enabling viewing of the manipulation procedure, means for modifying the proportions of gas in a multi gas chamber atmosphere set up in the main chamber, chamber heater means for heating the gas atmosphere in the main chamber, a recirculation gas circuit providing for recirculation of the main chamber gas atmosphere, the recirculation gas circuit including a particulate filter arrangement and a sterilization arrangement.01-14-2010
20090035854METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.02-05-2009
20120244619COMPOSITION FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS WHICH COMPRISES NITROVIN - The present invention provides a composition for promoting differentiation of pluripotent stem cells into cardiac muscle cells which comprises nitrovin, a method for inducing differentiation of pluripotent stem cells into cardiac muscle cells by using nitrovin and a method for preparing cardiac muscle cells by using nitrovin.09-27-2012
20100055787IN-VITRO PEARL PRODUCTION USING MARINE ORGANISMS - This invention in general relates to the production of pearls using marine organisms. More particularly, the present invention relates to in-vitro pearl production wherein shape, size and colour of the pearl can be controlled. A semi solid medium is used in the present invention which facilitates the bead to stand stationary and the cells grow over and around the bead and nacre is deposited within 15 days of initiation of cultures. Shell beads treated in organ cultures of mantle tissue of pearl oyster 03-04-2010
20110097797Modular Functional Peptides for the Intracellular Delivery of Nanoparticles - Described are peptides for delivery of a nanoparticle to the cytosol, the peptide comprising: (a) a nanoparticle association domain; (b) a proline-rich spacer domain; (c) an uptake domain; and (d) a vesicle escape domain comprising a non-hydrolyzable lipid moiety, wherein the spacer domain is between the nanoparticle association domain and the uptake and vesicle escape domains, and wherein the peptide, when attached to an extracellular nanoparticle, is effective to induce uptake of the nanoparticle by a cell and delivery of the nanoparticle to the cytosol of the cell. Also described are methods of delivery of a nanoparticle to the cytosol of a cell, the method comprising providing to a cell a nanoparticle attached to such a peptide. Exemplary nanoparticles include quantum dots.04-28-2011
20110151559Compounds for Modulating TRPV3 Function - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.06-23-2011
20090215174Methods of inhibiting umami taste receptors - Methods of inhibiting umami taste receptors are provided. These methods comprise contacting T1R1/T1R3 umami taste receptors with a sweet-taste inhibitor that also inhibits both the T1R1/T1R3 umami taste receptor and the T1R2/T1R3 sweet taste receptor.08-27-2009
20100068808Tubular nanostructure targeted to cell membrane - Devices, compositions, and methods are described which provide a tubular nanostructure or a composite tubular nanostructure targeted to a lipid bilayer membrane. The tubular nanostructure includes a hydrophobic surface region flanked by two hydrophilic surface regions. The tubular nanostructure is configured to interact with a lipid bilayer membrane and form a pore in the lipid bilayer membrane. The tubular nanostructure may be targeted by including at least one ligand configured to bind to one or more cognates on the lipid bilayer membrane of a target cell.03-18-2010
20110097798MAMMALIAN CELL EXPRESSION VECTORS AND UTILIZATION - An improved mammalian expression vector system which allows: (1) highly expressing exogenous proteins in host mammalian cells; (2) rapidly and efficiently screening recombinant stable cell lines expressing the gene of interest; (3) maintain sustainable expression and prevent gene silencing; and (4) effectively secreting proteins into media in some of cases. The entire expression vector system includes optimized promoters and core promoters, the use of special internal ribosome entry sites, integration of the bacterial backbone into the mammalian expression unit, multiple choices of selection markers, artificial matrix attachment region elements, effective secreting lead sequences and their 5′ and 3′ UTRs, and proper combinations of these expression elements.04-28-2011
20110076765METHOD FOR INCREASING THE ACTIVITY OF LYSOSOMAL ENZYMES - Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.03-31-2011
20110076766Cytostatic Drug Composition - A drug composition containing as a drug substance a polymeric guanidine derivative based on a diamine containing oxyalkylene chains between two amino groups, with the guanidine derivative representing a product of polycondensation between a guanidine acid addition salt and a diamine containing polyalkylene chains between two amino groups, as well as the pharmaceutically acceptable salts thereof.03-31-2011
20110151558METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS - The present invention concerns methods and compositions involving the production or generation of siRNA mixtures or pools capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include kits that include reagents for producing or generating siRNA pools. The present invention further concerns methods using polypeptides with RNase III activity for generating siRNA mixtures or pools that effect RNAi, including the generation of a number of RNA molecules to the same target gene.06-23-2011
20130164845Compositions and Methods for the Delivery of Biologically Active RNAs - Novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided. The novel compounds, vectors, cells, and compositions are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and/or treatment of diseases, discorders, or conditions in a subject or organism.06-27-2013
20100304485CELL ROLLING SEPARATION - The present invention provides systems for cell separation based on cell rolling on surfaces along edges of regions coated with cell adhesion molecules. A variety of designs of coated regions and edges are disclosed.12-02-2010
20110250685COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES - The present invention discloses compositions and methods for delivery of biomolecules into cells. Compositions comprise peptidomimetic macrocycles complexed or conjugated to biomolecules such as nucleic acids.10-13-2011
20100099188Dual Inhibitors of HIV-1 gp-120 Interactions - Compounds, which inhibit the binding of gp120 to CD4 as well as 17b and methods for their use in inhibiting the HIV fusion process, are provided.04-22-2010
20110151557COMPOSITIONS AND METHODS FOR TRANSFECTION OF RNA AND CONTROLLED STABILIZATION OF TRANSFECTED RNA - The present invention provides reagents and methods for RNA transfection and protein expression06-23-2011
20090317908HIGHLY PACKED POLYCATIONIC AMMONIUM, SULFONIUM AND PHOSPHONIUM LIPIDS - The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.12-24-2009
20090317907Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.12-24-2009
20090286316Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer - A novel gene (designated 158P3D2) and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.11-19-2009
20080293136NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF - The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing AKT gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an AKT mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an AKT gene in a cell or in a subject to treat an AKT-related disease.11-27-2008
20110159589METHODS OF INHIBITING INFLAMMATION WITH ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.06-30-2011
20090186409COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.07-23-2009
20080268536Humanized Anti-CCR2 Antibodies and Methods of Use Therefor - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.10-30-2008
20120276627SYNTHETIC MIMICS OF MIR-124 - Embodiments concern methods and compositions involving miR-124 mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-124 sequence and a complementary passenger strand.11-01-2012
20110027885SYSTEM AND METHOD FOR MICROMANIPULATING SAMPLES - A system and method for micromanipulating samples are described to perform automatic, reliable, and high-throughput sample microinjection of foreign genetic materials, proteins, and other molecules, as well as drawing genetic materials, proteins, and other molecules from the sample. The system and method overcome the problems inherent in traditional manual micromanipulation that is characterized by poor reproducibility, human fatigue, and low throughput. The present invention is particularly suited for adherent cell microinjection but can be readily extended to aspiration, isolation, and electrophysiological measurements of microorganisms, unicellular organisms, or cells.02-03-2011
20100285582VARIOUS HUMAN DENTAL STEM CELLS HAVING A MINERALIZATION ABILITY AND THE METHOD FOR CULTURING THEM - The present invention relates to various human dental stem cells having a mineralization ability and a method for culturing the same, more precisely postnatal stem cells having a mineralization ability, which are separated from human dental tissues such as dental pulp (DPSCs), periodontal ligament (PDLSCs), periapical follicle (PAFSCs) and mandibular bone marrow (MBMSCs) and a method for culturing the same under the optimum growth conditions. The human dental stem cells of the present invention can be obtained without additional injury as well as new stem cell sources such as teeth extracted from orthodontic purposes, prophylactically extracted nondecayed third molar teeth and discarded bone segments from orthognathic surgery, so that they can be effectively used for regeneration of injured teeth.11-11-2010
20100297761Novel Use of Liver X Receptor Agonists - A method of increasing the ex vivo viability of pancreatic islet cells comprising contacting the islet cells with a liver X receptor (LXR) agonist, particularly an LXRalpha agonist. Examples of especially useful LXR agonists include GW3965 and T0901317.11-25-2010
20110136229Novel lectin - The present invention discloses a lectin, which is isolated from a plant belonging to the family Caricaceae. The lectin of the present invention includes a first subunit having a molecular weight of 38 kDa and a second subunit having a molecular weight of 40 kDa, wherein the lectin has a molecular weight in a range from 750 to 850 kDa and has a binding specificity to N-acetylgalactosamine and lactose.06-09-2011
20110136231METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS - The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.06-09-2011
20110008891PARTIAL PEPTIDE OF LACRITIN - The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.01-13-2011
20100323442MODULATION OF THE PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY IN THE DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - Disclosed herein are cell cultures comprising differentiated human cells and methods of producing the same. The present invention provides compositions and methods for the production of differentiated human cells from human pluripotent cells. Preferably, the differentiated cells are selected from the group consisting of mesendoderm cells, definitive endoderm cells, ectoderm cells, trophectoderm cells, and extraembryonic endoderm cells.12-23-2010
20100330671MOLECULAR TRANSPORTERS BASED ON SUGAR AND ITS ANALOGUES AND PROCESSES FOR THE PREPARATION THEREOF - The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.12-30-2010
20110076767MAGNETICALLY-DRIVEN BIODEGRADABLE GENE DELIVERY NANOPARTICLES FORMULATED WITH SURFACE-ATTACHED POLYCATIONIC COMPLEX - A particle including a matrix-forming agent and a polyelectrolyte-amphiphilic agent adduct wherein the polyelectrolyte-amphiphilic agent adduct is in physical communication with the matrix-forming agent. The particle further includes a coated magnetic field-responsive agent and a biomaterial. Methods of making the particle are provided. Also provided are methods of delivery of the biomaterial to a target cell or a target tissue including administering the particle having the matrix-forming agent, polyelectrolyte-amphiphilic agent adduct, the coated magnetic field-responsive agent and the biomaterial; providing a magnetic device associated with the target cell or the target tissue; applying a magnetic force to the particle; and guiding the particle toward the magnetic device by the magnetic force.03-31-2011
20110076768METHOD FOR DETECTING CARCINOMA AND AGENT FOR SUPPRESSING CARCINOMA - An object of the present invention is to identify genes exhibiting characteristic behavior in the cases of carcinoma such as oral squamous-cell carcinoma using a change of expression level of micro RNA in oral squamous-cell carcinoma as an indicator, so as to provide a method for detecting carcinoma and an agent for suppressing carcinoma. The present invention A method for detecting oral squamous-cell carcinoma, which comprises detecting malignant transformation of specimens by employing a change of expression level of micro RNA as an indicator, and an agent for suppressing oral squamous-cell carcinoma using micro RNA.03-31-2011
20100184216hTERT GENE EXPRESSION REGULATORY GENE - Disclosed is a novel substance capable of regulating the expression of a telomerase reverse transcriptase gene in a cell of a mammal. A gene capable of regulating the expression of hTERT, comprising a nucleotide sequence depicted in SEQ ID No: 1 or 2. The expression of a telomerase reverse transcriptase gene can be inhibited by inhibiting the expression of the gene. By utilizing this mechanism, the expression of a telomerase reverse transcriptase gene can be regulated.07-22-2010
20090311784CYTOTOXIC RIBONUCLEASE VARIANTS - This invention relates to cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase1 hRI complex. Also disclosed is the 3-D structure of the hRI•RNase 1 complex and methods for designing the RNase 1 variants.12-17-2009
20090203133Determinants of Sensitivity to Chemotherapeutic Agents - The present invention provides methods for determining the level of resistance of a tumour cell to one or more chemotherapeutic agents, comprising measuring the level of expression of a muscle ankyrin repeat protein in the tumour cell. The invention also provides methods for increasing the sensitivity of a tumour cell to one or more chemotherapeutic agents, comprising administering to the cell an effective amount of an antagonist of a muscle ankyrin repeat protein. The invention further provides compositions for use in accordance with methods of the invention.08-13-2009
20090203132PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS - The present invention provides pyrrolidinyl compounds that are useful for preparing conjugated oligomeric compounds. The conjugated pyrrolidinyl compounds can be attached to support medium and provide a free hydroxyl for oligomer synthesis to prepare an oligmeric compound having a 3′-conjugate. Alternatively, the pyrrolidinyl compound can be prepared as a phosphoramidite which can be placed internally or at the 5′-position of an oligomeric compound. These two strategies can be used together to prepare oligomeric compounds having 2 or more conjugates at any selected positions. The present invention also provides methods for modulating gene expression using the conjugated oligomeric compounds.08-13-2009
20090203135Glycoconjugates of RNA Interference Agents - The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.08-13-2009
20120309086METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS - The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q10 or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q10 or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q10 in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.12-06-2012
20090176305COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES - Disclosed are novel compositions and novel methods for the creation of both the novel compounds and known compounds. Also disclosed are methods for use of the novel compounds for treating a variety of diseases relating to decreasing or preventing activation of estrogen receptors and/or estrogen related receptors.07-09-2009
20090197332Modified Short Interfering RNA - The present invention refers to a double-stranded siRNA molecule comprising a sense Strand and an antisense Strand which is essentially complementary to the sense Strand, each of the sense and the antisense Strands comprising at least 17 nucleotides (nt), the siRNA further comprising at least one overhang at the 5′ and/or 3′ end, wherein the overhang residue or overhang residues are chemically modified and selected independently from each other from the group consisting of: (a) 2′-deoxy modified nucleotides; (b) 2′-methoxy modified nucleotides; (c) two nucleosides linked by a 3′ to 5′ or 2′ to 5′ formacetal linkage; (d) nucleotides modified at the 2′-position by a -0-CH08-06-2009
20120309087CANCER THERAPY - The present invention relates to an improved assay for identifying compounds that may be of use in conjunction with cancer chemotherapeutic agents and anti-proliferative agents, to improve efficacy of such agents and/or render effective compounds with relatively little therapeutic activity. There is also provided a class of compounds identified by said assay which may be used in a combination therapy, with current and novel agents, to treat cancers and other diseases associated with abnormal host cell proliferation, such as psoriasis.12-06-2012
20110189771Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity and Reducted Toxicity - Imino sugars, such as deoxynojirimycin (DNJ), are glucose analogues that selectively inhibit cellular α-glucosidase I and II (enzymes that process N-linked glycans in glycoprotein) and exhibit broad spectrum antiviral activities against many enveloped viruses. Previously we have reported a novel DNJ derivative, OSL-95II, with antiviral activity and reduced cytotoxicity. In order to develop imino sugars with more potent antiviral activity as well as improved toxicity profile, OSL-95II was modified by diversifying the nitrogen linked alkylated side chain. The antiviral activities were initially tested in bovine viral diarrhea virus (BVDV) infected MDBK cells, yielding several imino sugar derivatives with novel structure and superior antiviral activity and toxicity profile. Furthermore, these new compounds were shown to be active against Dengue virus (DV) and West Nile virus (WNV) infection in BHK cells where potent anti-DV activity having submicromolar EC50 values and SI of greater than 900. These compounds represent a new generation of iminio sugars and their analogues, having application in the clinical treatment of infection of DV and other members of flaviviridae.08-04-2011
20110189770Endosome-Disrupting Compositions and Conjugates - The present invention is directed to an endosome-disrupting conjugate, and methods of delivery of said conjugate to cells. The conjugates of the invention comprise a payload and an endosome-disrupting component of which the latter comprises a plurality of moieties that react under acidic conditions, e.g., within an endosome, to release gaseous endosome-disrupting molecules, e.g., CO08-04-2011
20110189769METHODS AND COMPOSITIONS FOR MANIPULATING THE GUIDED NAVIGATION OF ENDOTHELIAL TUBES DURING ANGIOGENESIS - Methods and compositions for manipulating the directed navigation of physiological tracking tubular structures are provided. A novel cell-bound receptor, roundabout-4 (Robo-4), is described. The Robo-4 receptor shows sequence and structural similarity to members of the roundabout family of receptors. Also, the Robo-4 receptor binds Slit ligand, a known receptor of the roundabout receptors. Polynucleotides and polypeptides of the Robo-4 receptor are described.08-04-2011
20110136230Cultured Hematopoietic Stem Cells and Method for Expansion and Analysis Thereof - Hematopoietic stem cells and methods for ex vivo expansion of hematopoietic stem cells are provided. The methods comprise culturing the cells in a media containing an effective amount insulin-like growth factor(IGF), fibroblast growth factor (FGF), thrombopoietin (TPO), and stem cell factor (SCF), under conditions sufficient for expansion of said cells. Methods for identifying expanded hematopoeitc stem cells and kits for ex vivo expansion of hematopoietic stem cells are also provided.06-09-2011
20100028998RNAi Expression Constructs - The present invention provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues or organs of interest in vitro and in vivo so as to treat diseases or disorders.02-04-2010
20100022002METHOD FOR INHIBITING THE FORMATION OF SET1 FAMILY CORE COMPLEXES - Disclosed in this specification is a method for inhibiting the formation of SET1 family core complexes. A guanidinium-containing molecule is used to competitively inhibit the binding of the N-SET region of a SET1 protein to WDR5, thus inhibiting the formation of the SET1 family core complex. The guanidinium-containing molecule may be, for example, an arginine-containing peptide. When bound to WDR5, the guanidinium moiety is bound between the F-133 and F-263 residues of the WDR5 when a crystal structure of the bound complex is obtained.01-28-2010
20080268537PRIMARY N-HYDROXYLAMINES - The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.10-30-2008
20100311167ELECTROKINETICALLY-ALTERED FLUIDS COMPRISING CHARGE-STABILIZED GAS-CONTAINING NANOSTRUCTURES - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized gas-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids. The electrokinetically-altered fluid compositions and methods of producing the fluid include electrokinetically-altered ionic aqueous fluids optionally in the form of solvated electrons stabilized, at least in part, with molecular gas (e.g., oxygen).12-09-2010
20100285583COMPOUNDS AND METHODS FOR INHIBITING PLATELET AGGREGATION - The present invention relates to compounds and methods for inhibiting platelet aggregation. In an embodiment, the compound of the present invention contains the sulfatide binding region of the N-terminal phosphotyrosine binding domain (N-PTB) of Disabled-2 (Dab2).11-11-2010
20090203136MODULATING IMMUNE SYSTEM DEVELOPMENT AND FUNCTION THROUGH MICRORNA MIR-146 - The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.08-13-2009
20110117649Catalytic enantioselective synthesis of flavanones and chromanones - Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.05-19-2011
20110117648SINGLE CELL SURGERY TOOL AND A CELL TRANSFECTION DEVICE UTILIZING THE PHOTOTHERMAL PROPERTIES OF THIN FILMS AND/OR METAL NANOPARTICLES - This invention provides novel tools for surgery on single cells. In certain embodiments the tools comprise a microcapillary having at and/or near the tip a metal coating or a plurality of nanoparticles that can be heated by application of electromagnetic energy. In certain embodiments substrates are provided that facilitate the introduction of agents into cells. The substrates typically comprise a surface bearing a film or particles or nanoparticles that can be heated by application of electromagnetic energy.05-19-2011
20090298177DAT1 - A synthetic diaminoketothiazole, its process of preparation and its use as a microtubule inhibitor, a probe for tubulin-microtubule system and a cytotoxic agent. Diaminoketothiazole of the formula (I) wherein Ar is 4-OMe-C12-03-2009
20120301961POLYPEPTIDE HAVING AFFINITY FOR ENVELOPE VIRUS CONSTITUENT AND USE THEREOF IN TRANSFERRING SUBSTANCE INTO CELL - Delivery proteins are provided for transferring a protein, antibody or foreign substance into a cell without impairing the function or structure thereof. Further, methods of transferring a foreign substance into a cell at a high efficiency by using the delivery protein or an envelope virus or inactivated envelope virus in combination with said delivery protein are provided. The inventors discovered that a protein containing a polypeptide having an affinity for a constituent of the envelope virus contributes to the efficient enclosure of the foreign substance in the envelope. Moreover, the inventors discovered that use of the delivery protein enables foreign substances to be included in an envelope virus or inactivated envelope virus and therefore makes it possible to efficiently transfer the substances into cells without damaging the physiological function thereof.11-29-2012
20120301960Lance Device and Associated Methods for Delivering a Biological Material Into a Cell - Systems, devices, and methods for delivering a biological material into a cell are provided. In one example, a lance device for introducing biological material into a cell and configured for use in a nanoinjection system including a microscope is provided. Such a device can include a lance having a tip region and a shaft region, wherein the lance is structurally configured to allow entry and movement of the tip region into the cell along an elongate axis of the tip region and along a focal plane of the microscope. In another example, the lance can be configured to allow substantially horizontal entry and movement of the tip region into the cell.11-29-2012
20120040460Ribonucleic Acid Interference Molecules - Ribonucleic acid interference molecules are provided. In one aspect of the invention, a method for regulating gene expression comprises the following step. At least one nucleic acid molecule comprising at least one of one or more precursor sequences having SEQ ID NO: 1 through SEQ ID NO: 103,948, each one of the precursor sequences containing one or more mature sequences having SEQ ID NO: 103,949 through SEQ ID NO: 230,447, is used to regulate the expression of one or more genes.02-16-2012
20090298174Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.12-03-2009
20110318839METHOD FOR ENHANCING A FUNCTION OF A T CELL - Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.12-29-2011
20110318838CELL-TYPE SPECIFIC APTAMER-siRNA DELIVERY SYSTEM FOR HIV-1 THERAPY - The present invention relates to compositions and methods for delivery of siRNA to specific cells or tissue. More particularly, the present invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer.12-29-2011
20110318835Implant Surface Treatment Method Having Tissues Integrated - The present disclosure uses different kinds of surface treatment processes on titanium-made dental implants. The growth and attachment conditions of bone cells (MC3T3-E), fibroblasts(NIH 3T3) and epidermal cells (XB-2) on the metal surface of titanium slices with different surface treatments are observed. Tetra-calcium phosphate is used to perform secondary sand-blasting process to clean up the metal surface and provide calcium ions for osteoblastoma physiology. Thus, by adjusting the cells adhesive and proliferative abilities, the success rate of the clinical applications in dental implant is improved.12-29-2011
20110318837METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS BY STIMULATING ER STRESS - The present invention provides a method for inducing apoptosis in selected cells by aggravating ER-stress. The aggravation of ER-stress is achieved in a specific manner by inhibiting SERCA (sarcoplasmic/endoplasmic reticulum calcium ATPase), leading to elevated level of cytoplasmic calcium concentration, yet without inhibiting the activity of COX-2 (cyclooxygenase-2) or triggering the release of histamine. Induction of apoptosis may be enhanced by first inducing or further aggravating ER-stress through inhibition of proteasome or proteases. Also provided are compounds and compositions useful as ER-stress aggravating agents, methods for screening, selecting, identifying and designing the same and methods for treating diseased conditions by inducing apoptosis through specific and selective aggravation of ER-stress.12-29-2011
20110318834Multiple-tumor aberrant growth genes - The invention relates to the multi-tumor aberrant growth gene having the nucleotide sequence of any one of the strands of any one of the members of the High Mobility Group protein genes or LIM protein genes, including modified versions and derivatives thereof. The gene and its derivatives may be used in various diagnostic and therapeutic applications.12-29-2011
20110318836METHOD OF ENRICHING SPERMATOZOA OF MAMMALS BEARING X-CHROMOSOME OR Y-CHROMOSOME - The present invention relates to an immunological method that selects spermatozoa having X-chromosome or Y-chromosome. The method of the invention is based on the use of monoclonal antibodies directed against the genus-specific proteins located in the cytoplasm membrane of spermatozoa associated to the action of the classical complement pathway to increase the percentage of one of the gender in the offspring of mammals.12-29-2011
20120009678IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.01-12-2012
20110008888Novel Genetic Approaches to Reduce or Inhibit Tumorgenicity of Human Embryonic Stem Cells and Derivatives Following Transplantation - Self-renewable embryonic stem cells (ESCs), derived from the inner cell mass of blastocysts, can propagate indefinitely in culture while maintaining their normal karyotypes and pluripotency to differentiate into all cell types. Therefore, ESCs may provide an unlimited supply of even specialized cells such as brain and heart cells for transplantation and cell-based therapies that are otherwise limited by donor availability. However, this promising application is hampered by concerns that ESCs or their multipotent derivatives also possess the potential to form malignant tumors after transplantation in vivo. The present invention provides for a novel genetic method to arrest undesirable cell division (of ESCs and other unwanted lineages) as a means to inhibit or eliminate their tumorgenic potential after transplantation.01-13-2011
20120009679Tissue Implants for Implantation and Methods for Preparing the Same - A method is provided for preparing a tissue implant for implantation. The method includes harvesting a tissue material from a human or an animal donor, treating the tissue material in a nuclease-containing solution, and thereafter treating the tissue material with an alkaline alcohol solution. The nuclease-containing solution includes an antimicrobial. The alkaline alcohol solution comprises sodium hydroxide and ethanol.01-12-2012
20120009680Cancerous Disease Modifying Antibodies - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, inteerferons, target or reporter moieties and hematogenous cells.01-12-2012
20090023210B-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN - The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of β-cyclodextrin. Per-substituted alkylamino derivatives displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition of one of the alkylamino derivatives to the bilayer lipid membrane with multiple PA channels caused a significant decrease in membrane conductance. Thus, the invention also provides methods for protection against anthrax toxicity.01-22-2009
20100009446BIOLOGICALLY ACTIVE MOLECULES, PARTICULARLY BASED ON PNA AND SIRNA, METHOD FOR THE CELL-SPECIFIC ACTIVATION THEREOF, AND APPLICATION KIT TO BE ADMINISTERED - Biologically active molecules are inactivated for selective activation by target cells by being covalently bonded to one or more peptides each of which has one or more specific amino acid sequences that are selected in respect of enzymes cell-specific for target cells. The bonds, which are broken exclusively by the enzymes cell-specific for the target cells in order to biologically activate the molecules, allow the molecules to remain biologically inactive in cells other than the target cells. The molecules are used for influencing gene expression of preferably sick and infected organs or cells, for example.01-14-2010
20110165675CAPPING BIOPROSTHETIC TISSUE TO REDUCE CALCIFICATION - A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.07-07-2011
20120064625Nucleic Acids, Polypeptides, Compositions, and Methods for Modulating Apoptosis - The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.03-15-2012
20120064626B7-H7 ANTIBODIES AND METHOD OF USE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.03-15-2012
20110091970METHYLATION OF ESTROGEN RECEPTOR ALPHA AND USES THEREOF - Methods for diagnosis, prognosis, and treatment of cancer based on the methylation status of the ER-α gene promoter are disclosed. Methylation of the ER-α gene promoter is indicative of cancer and unfavorable prognosis. The cancer can be treated with a demethylation agent.04-21-2011
20100022001Cationic Liposomes And Method of Use - Highly efficient cationic liposomes are provided as a system for the delivery to cells of agents or compounds, such as, compounds capable of silencing a target protein and enzyme substrates. The cationic liposomes can be used in methods of detecting the inhibition activity or apparent activity of a target protein in a cell, and methods of identifying a protein associated with a pathway, such as, a signal transduction pathway in a cell.01-28-2010
20110065189Lacritin-Syndecan Interactions - The present invention relates to methods and compositions useful for the regulation of lacritin, syndecan, and lacritin-syndecan interactions and the signaling pathway downstream of lacritin-syndecan interactions. The invention also relates to regulating lacritin-syndecan interaction to regulate ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.03-17-2011
20110104802PROCEDURE FOR THE UNDIFFERENTIATED OR MYELOID LINEAGE BIASED EXPANSION OF HAEMATOPOIETIC STEM CELLS FROM UMBILICAL CORD BLOOD, MOBILIZED PERIPHERAL BLOOD OR BONE MARROW - Procedure for the undifferentiated or myeloid lineage biased expansion of haematopoietic stem cells coming from umbilical cord blood, mobilized peripheral blood or bone marrow.05-05-2011
20110104801METHODS AND COMPOSITIONS FOR CELL-CYCLE REGULATION - In some aspects, the invention provides methods and compositions including HTm4, an HTm4 activator, and/or an HTm4 variant to potentiate a KAP phosphatase activity and or inhibit a CDK2 kinase activity. In some embodiments, a functional C-terminal fragment of HTm4 is provided. In other aspects, the invention provides methods and compositions including an HTm4 inhibitor to inactivate or decrease the activation of a KAP phospatase activity and/or activate or relieve the inhibition on a CDK2 kinase activity. Certain aspects of the invention relate to therapeutic compositions and methods for either inhibiting or promoting cell proliferation.05-05-2011
20100093087IL-17 Mediated Transfection Methods - The invention comprises compositions and methods for IL-17-mediated transfection that results in superior and enhanced properties of cell survival and protein production.04-15-2010
20100093086Stapled Peptides and Method of Synthesis - A method for preparing stapled peptides. The stapled peptides, including helical stapled peptides, are prepared according to a photochemically-based method, a [3+2] cycloaddition reaction. The helical stapled peptides exhibit increased helicity, thermal stability and cell permeability.04-15-2010
20100093085TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE - Provided herein are tripartite oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene. The tripartite oligonucleotide complexes of the disclosure may include a conjugate moiety that facilitates delivery to a cell, tissue or organism without the aid of a transfection reagent04-15-2010
20120122216OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.05-17-2012
20120122217METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS - The present invention concerns methods and compositions involving the production or generation of siRNA mixtures or pools capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include kits that include reagents for producing or generating siRNA pools. The present invention further concerns methods using polypeptides with RNase III activity for generating siRNA mixtures or pools that effect RNAi, including the generation of a number of RNA molecules to the same target gene.05-17-2012
20110129920BIOMARKERS FOR ALZHEIMER'S DISEASE - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).06-02-2011
20120214234iPS CELLS AND METHOD FOR PREPARING THE SAME - The present invention provides a method for producing iPS cells, comprising reacting cells with at least one connexin inhibitor and at least one TGFβ signaling inhibitor; iPS cells comprising at least one connexin inhibitor; an iPS cell inducer comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGFβ signaling inhibitors; a medium for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGFβ signaling inhibitors; and a kit for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGFβ signaling inhibitors.08-23-2012
20110183416Method of modulating the proliferation of medullary thyroid carcinoma cells - The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A preferred selective somatostatin receptor type-2 (SSTR-2) agonist cyclo[Tic-Tyr-D-Trp-Lys-Abu-Phe] is also disclosed.07-28-2011
20120164730COMPOSITIONS FOR SILENCING THE EXPRESSION OF VDAC1 AND USES THEREOF - The present invention relates generally to the down regulation of mitochondrial protein, voltage-dependent anion channel (VDAC1) expression by RNAi or antisense therapy. In particular, the present invention is directed to VDAC1 silencing molecules useful in regulating cell proliferation and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant cell proliferation.06-28-2012
20100210015PHOTOCHEMICAL ACTIVATION OF SURFACES FOR ATTACHING BIOMATERIAL - A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.08-19-2010
20100081198METHOD FOR THE REPAIR OF MUTATED RNA FROM GENETICALLY DEFECTIVE DNA AND FOR THE SPECIFIC DESTRUCTION OF TUMOR CELLS BY RNA TRANS-SPLICING, AND A METHOD FOR THE DETECTION OF NATURALLY TRANS-SPLICED CELLULAR RNA - Methods and products for the repair of genetically defective DNA in the region of a mutated exon, for the specific destruction of tumor cells, and for the identification of naturally trans-spliced RNA. The methods inter alia are based on the utilization of cellular RNA splicing components.04-01-2010
20120135522METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 - Disclosed herein are methods of inhibiting the function of p53 in a cell by contacting the cell with an effective amount of a PP2A inhibitor. Also disclosed herein are processes for producing an induced pluripotent stem (iPS) cell by contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to produce the iPS cell; reversibly inhibiting p53 function during production of an iPS cell by contacting a somatic cell with an amount of a PP2A inhibitor effective to reversibly inhibit p53 function; increasing the likelihood of producing an (iPS) cell.05-31-2012
20120220034Methods for Reprogramming Cells and Uses Thereof - Described herein are methods for cell dedifferentiation, transformation and eukaryotic cell reprogramming Also described are cells, cell lines, and tissues that can be transplanted in a patient after steps of in vitro dedifferentiation and in vitro re-programming In particular embodiments the cells are Stem-Like Cells (SLCs), including Neural Stem-Like Cells (NSLCs) Also described are methods for generating these cells from human somatic cells and other types of cells Also provided are compositions and methods of using of the cells so generated in human therapy and in other areas.08-30-2012
20120220033INHIBITION OF VIRAL GENE EXPRESSION USING SMALL INTERFERING RNA - The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described.08-30-2012
20090029467Method for targeting lysosomal enzymes - Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.01-29-2009
20130171728Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.07-04-2013
20120077270Control of Gene Expression Using a Complex of an Oligonucleotide and a Regulatory Peptide - A method for suppressing the expression of a selected gene in a cell, the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.03-29-2012
20120214235METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.08-23-2012
20120214233CYSTATIN C AS AN ANTAGONIST OF TGF-BETA AND METHODS RELATED THERETO - Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases.08-23-2012
20120252119METHODS FOR THE COLLECTION AND MATURATION OF OOCYTES - The present invention relates to a method of producing an embryo from an oocyte by an assisted reproduction technology. The method includes (a) collecting an oocyte from an ovary of a subject in a collection medium comprising a first phosphodiesterase inhibitor and an agent that increases intracellular cAMP concentration in the oocyte, (b) culturing the oocyte in a maturation medium comprising a second phosphodiesterase inhibitor, and (c) producing an embryo from the oocyte by an assisted reproduction technology. The present invention also relates to methods of inducing oocyte maturation. For example a method of in vitro maturation of an oocyte is described which comprises steps (a) and (b) above. The present invention also relates to an oocyte maturation medium comprising a phosphodiesterase inhibitor and a ligand for inducing maturation of the oocyte. A combination product comprising an oocyte collection and maturation medium referred to above is also described.10-04-2012
20120178163Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same - The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptides molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.07-12-2012
20100009445RARE EARTH NANOPARTICLES - This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided.01-14-2010
20100009444SYSTEM AND METHOD FOR CONTROLLING G-PROTEIN COUPLED RECEPTOR PATHWAYS - A light-sensitive G-protein coupled receptor includes a light sensitive extracellular domain and a heterologous intracellular domain capable of modulating an intracellular signaling pathway.01-14-2010
20090061515Methods of inhibiting or suppressing cellular proliferation - Methods of inhibiting or suppressing cellular proliferation are disclosed that include delivering at least one antiproliferative agent into or proximate a cell. In certain embodiments, the antiproliferative agent(s) are hydrolysis products of a biodegradable polymer (e.g., a polyketal polymer).03-05-2009
20100291680METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION - The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-111-18-2010
20120225482MAMMALIAN CX3C CHEMOKINE ANTIBODIES - Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.09-06-2012
20120258535METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.10-11-2012
20120258534METHOD OF DELIVERING RNA INTERFERENCE AND USES THEREOF - The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.10-11-2012
20120190110IMMUNOLOGICAL USES OF IMMUNOMODULATORY COMPOUNDS FOR VACCINE AND ANTI-INFECTIOUS DISEASE THERAPY - Methods of enhancing immune response to an immunogen in a subject are disclosed. Also disclosed are methods of reducing the sensitivity to an allergen in a subject. The methods comprise the administration of an immunomodulatory compound in specific dosing regimens that result in enhanced immune response or reduced sensitivity.07-26-2012
20120264212COMPOUNDS AND METHODS FOR INHIBITING THE METASTASIS OF CANCER CELLS - The present invention relates to compounds and methods for inhibiting cancer metastasis. In an embodiment, the compound of the present invention contains the sulfatide binding region of the terminal phosphotyrosine binding domain (N-PTB) of Disabled-2 (Dab2).10-18-2012
20090017538Mammalian MDM2 Binding Proteins and Uses Thereof - Isolated nucleic acid sequences encoding mammalian binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G01-15-2009
20110124104INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE - Provided herein is a method for inducing cell death by inducing heat shock response in a cell in combination with inhibiting adaptive heat shock response. Also provided are methods for preventing cancer, treating intracellular parasite infections, and inflammation-associated conditions.05-26-2011
20110039334CHIMERIC OLIGOMERIC COMPOUNDS FOR MODULATION OF SPLICING - Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.02-17-2011
20100055788METHOD AND APPARATUS FOR INFILTRATING TISSUE SAMPLES WITH PARAFFIN - A method and an apparatus are described for infiltrating tissue samples with carrier material, preferably paraffin. A supply of carrier material is kept ready for use in a supply station. From there, the carrier material can be delivered into at least a first and a second container. In these first and second containers carrier materials of differing degrees of purity are kept ready for use, respectively, for performing various infiltration steps on tissue samples. By means of the described method and apparatus the tissue processor can be operated with as little interruptions as possible and an ease in operation is achieved.03-04-2010
20110003385REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS - Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the ζ chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene.01-06-2011
20110039335Compositions and Methods for Inhibiting Cell Migration - The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.02-17-2011
20120322153REPROGRAMMING A CELL BY ACTIVATION OF THE ENDOGENOUS TRANSCRIPTION FACTOR NETWORK - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises delivering a transcription factor to a cell and exposing said cell to an agent that inhibits the activity, expression, or activity and expression of a gene, which codes for a protein, or a protein involved in transcriptional repression, and selecting a cell, wherein differentiation potential has been restored to said cell. In yet another embodiment, the invention relates to a reprogrammed cell and an enriched population of reprogrammed cells that can have characteristics of an ES-like cell can be re- or trans-differentiated into various differentiated cell types.12-20-2012
20110045590CALCIUM-INFLUX INHIBITORY FACTOR AND METHOD OF ISOLATION THEREOF - A purified factor isolated from human milk is provided. The factor is capable of inhibiting calcium-influx activity in polymorphonuclear leukocytes. A method for purification of the factor is also provided.02-24-2011
20120270318ION CHANNEL MODULATORS AND METHODS OF USE - In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.10-25-2012
20120270317ALTERNATIVE EXPORT PATHWAYS FOR VECTOR EXPRESSED RNA INTERFERENCE - The present invention is directed to nucleic acid molecules containing a loop sequence designed to circumvent exportin-5 mediated export, and methods using these novel molecules.10-25-2012
20100203637Fluorescent cell markers - The preparation and use of fluorescent cell markers of the structure F—S08-12-2010
20110223665ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND - One aspect of the present invention relates to a double stranded nucleic acid useful as an siRNA, that has a sense strand and an antisense strand relative to a target nucleic acid, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one nucleoside comprising a non-natural nucleobase. Another aspect of the invention relates to a method of gene silencing, comprising administering to a mammal in need thereof a therapeutically effective amount of a double-stranded oligonucleotides containing a sense strand and an antisense strand, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand.09-15-2011
20110236973Centrosome proteins and uses thereof - The invention includes nucleic acids and polypeptides that play important roles in centrosomes and cellular functions involving centrosomes. In addition, the invention encompasses antibodies, ribozymes, antisense nucleic acids, RNAis, and siRNAs that can be used to modulate the function of the nucleic acids and polypeptides of the invention. Such modulation can be useful in detecting, diagnosing, and treating abnormal centrosome function.09-29-2011
20100233810IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING - The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.09-16-2010
20100233809CYTOTOXIC RIBONUCLEASE VARIANTS - This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.09-16-2010
20090075377MOLECULAR INTERACTIONS IN CELLS - The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in cells, particularly interactions between a PDZ protein and a PL protein. Reagents and methods that are provided are useful for treatment of a variety of diseases and conditions in a variety of cell types.03-19-2009
20100216238COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING - Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.08-26-2010
20120329154MACROPHAGE PHAGOCYTOSIS-ACTIVATING COMPOSITION AND/OR COMPOSITION PROMOTING CYTOKINE PRODUCTION IN MACROPHAGES - Disclosed is a highly effective macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages using an active component derived from natural products. A culture obtained by culturing microorganisms belonging to the genus 12-27-2012
20120100609N-LINKED GLYCAN BIOSYNTHESIS MODULATORS - Provided herein are N-linked glycan inhibitors, including modulators of N-linked glycan glycosylation, mannosidase, an N-linked glycan N-acetylglucosaminyl transferase, an N-linked glycan fucosyl transferase, an N-linked glycan galactosyl transferase, an N-linked glycan sialyl transferase, an N-linked glycan sulfotransferase, N-linked glycan glycophosphotransferase or a combination thereof.04-26-2012
20120100608LYMPHOCREME - The mixture is a topical crème for use in the treatment of cutaneous T-cell Lymphoma.04-26-2012
20120135521ANTIGENE LOCKS AND THERAPEUTIC USES THEREOF - An oligonucleotide based therapeutic strategy, called anti-gene locks, is described which specifically kills cells based on their genotype. The strategy employs oligonucleotides with arms and a backbone that are complementary to both strands of the gene target. Anti-gene locks bind in vitro in a sequence dependent fashion and inhibit DNA synthesis. In bacterial cells containing an episome target, they cause elimination of the extra-chromosomal DNA structure. When the target is present in the bacterial or human genome, they selectively kill the majority of these cells.05-31-2012
20100167400Composition for Increasing Intracellular Nitric Oxide and Method for the Same - A composition and a method for increasing intracellular nitric oxide is provided. The composition comprises a far-infrared ray releasing substance composed mainly of an oxide mineral for releasing a far-infrared ray, wherein the composition promotes generation of the nitric oxide via irradiation of the far-infrared ray from the far-infrared ray releasing substance. In another aspect, the method comprises setting an effective amount of a far-infrared ray releasing substance in a place close to a cell with an appropriate distance, and incubating the far-infrared ray releasing substance with the cell for a specific period, wherein the appropriate distance lies in an irradiation range of the far-infrared ray releasing substance.07-01-2010
20130011923MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.01-10-2013
20100129909DEVICE AND METHOD FOR TREATING BIOMASS - A method for pretreating and disrupting cell structure of biomass by subjecting the biomass to high pressure, thereby disrupting the cell structure of the biomass is provided. Also provided is a device for performing the method, wherein the device includes a cavitating device and a cell structure disrupting device disposed within the cavitating device for disrupting the cell structure and exposing the internal cell structure to enzymes.05-27-2010
20120149109MODULATION OF TRANSTHYRETIN EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.06-14-2012
20130017602MODULATION OF OOCYTE MEIOTIC PROGRESSION AND OOCYTE ACTIVATION - The present invention provides methods, compositions, and systems for reinitiating meiosis in cells in meiotic arrest and oocyte activation in fertilized, but un-activated, oocytes. In certain embodiments, Zn-binding moieties (e.g., zinc chelators) are used for reinitiating meiosis or oocyte activation.01-17-2013
20130017603GLUTAMATE DERIVATIVES OR SALTS THEREOF - Compounds having an excellent CaSR agonist activity are in demand. The invention provides glutamate derivatives or salts thereof, pharmaceutical compositions comprising the glutamate derivatives, preventive or therapeutic agents for diarrhea, hyperparathyroidism or peptic ulcer.01-17-2013
20130017601MODULATION OF PLASMA MEMBRANE HUMAN LEUKOCYTE ELASTASE - A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein.01-17-2013
20110159588Methods for Modulating a PDGF-AA Mediated Biological Response - The present invention is directed towards methods and means for modulating PDGF-AA mediated biological responses and is based, at least in part, on examining the association of various proteins with TMEFF2 and identification of PDGF-AA as a major growth factor that interacts specifically with TMEFF2. The invention provides the first evidence that TMEFF2 can function to regulate PDGF signaling, to help illuminate the seemingly conflicting biological roles of TMEFF2 in human cancers.06-30-2011
20110159587Chimeric Molecules to Modulate Gene Expression - The present invention provides a chimeric molecule including a base-pairing segment that binds specifically to a single-stranded nucleic acid molecule; and a moiety that modulates splicing or translation. The invention also provides a chimeric molecule including a base-pairing segment that binds specifically to a double-stranded nucleic acid molecule; and a peptide that modulates transcription, wherein the peptide comprises up to about one hundred amino acid residues.06-30-2011
20110159586COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION USING ASYMMETRICALLY-ACTIVE PRECURSOR POLYNUCLEOTIDES - The present invention is directed to novel nucleic acid molecules which include a region complementary to a target gene and one or more self-complementary regions, and the use of such nucleic acid molecules and compositions comprising the same to modulate gene expression and treat a variety of diseases and infections.06-30-2011
20080233645Methods and Compositions of Ig20 and Denn-Sv Splice Variants - Methods and compositions relating to IG20 expression, splice variants of IG20, effects of endogenous DENN-SV function with respect to processes regulating cell proliferation, cell survival and cell death are disclosed.09-25-2008
20080227201In vitro model for neuronal death - This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling. The formation of this signaling module is dependent on cholesterol for its formation and provides a mechanistic explanation for the protective effects of cholesterol depleting drugs in several non-neural models of cell death. As such, the formation of the signaling module lends itself as a novel screen for the identification of new drugs and therapeutics which would retard its formation and protect against neuronal injury and death.09-18-2008
20080227200Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same - A gene encoding a polypeptide having an activity to support proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells is isolated by comparing expressed genes between cells which support proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells and cells which do not support the proliferation or survival. Proliferation or survival of hematopoietic stem cells or hematopoietic progenitor cells is supported by using stromal cells in which the isolated gene is expressed or a gene product of the isolated gene.09-18-2008
20080227199Method for simultaneous production of multiple proteins; vectors and cells for use therein - Described is the production of proteins in a host cell. More specifically, described are methods for improving expression of two or more proteins in a cell or host cell. The methods are suited for production of, for example, recombinant antibodies that can be used in pharmaceutical preparations or as diagnostic tools. In one embodiment, provided is a method for obtaining a cell that expresses two or more proteins comprising providing the cell with two or more protein expression units encoding two or more proteins, characterized in that at least two of the protein expression units comprise at least one STAR sequence.09-18-2008
20080227198IMMUNOREGULATORY ANTIBODIES AND USES THEREOF - A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.09-18-2008
20080248569SELF-ASSEMBLING PEPTIDE AMPHIPHILES FOR TISSUE ENGINEERING - The present invention provides for compositions and methods for creating self-assembled peptide amphiphile (PA) structures. In particular, the present invention provides for two and three-dimensional structures of crosslinked PA microtexture structures useful for tissue engineering and drug discovery.10-09-2008
20130177984Tumor Suppressor Gene, p28ING5 - This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.07-11-2013
20130143319Use of Functional Nanoelectrodes for Intracellular Delivery of Chemical and Biomolecular Species - The invention provides methods of controlled release of an agent into an intracellular environment of a biological cell using a needle nanoelectrode. The agent may be attached to an outer surface of the needle nanoelectrode through a linking molecule, wherein the attachment comprises an electroactive chemical bond. After penetrating a cellular membrane with the needle nanoelectrode to position at least a portion of the nanoelectrode in the intracellular environment, an electric potential may be applied to the needle nanoelectrode to break the electroactive chemical bond, thereby releasing the agent to the intracellular environment. The linking molecule may be a surface active organosulfur compound capable of forming a self-assembled monolayer on a metal surface of the nanoelectrode06-06-2013
20080213890Antibody-avidin fusion proteins as cytotoxic drugs - Methods and compositions for inducing apoptosis and/or inhibiting proliferation of cells. The method includes exposing the cells to a cytotoxic agent which is made up of a targeting moiety and an avidin moiety wherein the targeting moiety is capable of binding to one or more receptors located on the cells. The invention is based on the discovery that attaching an avidin moiety to non-toxic targeting moieties produces a cytotoxic agent which can be used to treat tumor cells both in vivo and in vitro. The present cytotoxic agent eliminates the use of biotinylated toxic drugs which previously have been conjugated to antibody-avidin targeting vehicles.09-04-2008
20130137175METHODS OF INDUCING LEUKEMIA AND LYMPHOMAS AND DETECTING SUSCEPTIBILITY TO LEUKEMIA/ LYMPHOMA - A diagnostic test is described using 05-30-2013
20130137174NUCLEOTIDE-SPECIFIC RECOGNITION SEQUENCES FOR DESIGNER TAL EFFECTORS - The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.05-30-2013
20110269229METHODS OF INHIBITING VIRAL REPLICATION - The instant invention provides methods for the treatment and prevention of viral infection, e.g., HIV infection, based on the discovery that viral replication utilizes the ubiquitination pathway of the host cell to replicate. Specifically, the invention provides methods for the treatment and prevention of viral infection, e.g., HIV infection, by modulation of ISG15 conjugation and deconjugation, e.g., by modulation of the activity or expression of UBP43 or UBEL-1.11-03-2011
20130115696siRNA that Inhibits WT1 Gene Expression and Uses Thereof - The present inventors discovered that siRNAs targeting the 17AA site of the WT1 gene not only suppress the expression of the WT1 gene, but also demonstrate remarkable cell growth-suppressing effects and cell death-inducing effects in cancer cell lines.05-09-2013
20130130378OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS - This invention relates to acyclic and abasic nucleosides and oligonucleotides prepared therefrom. For instance, oligonucleotides can be prepared having one or more of the following formulas (I-III):, or isomers thereof.05-23-2013
20130130377NOVEL SIRNA STRUCTURE FOR MINIMIZING OFF-TARGET EFFECTS CAUSED BY ANTISENSE STRANDS, AND USE THEREOF - The present invention relates to a novel siRNA structure and the use thereof, and more particularly to a double-stranded siRNA molecule comprising an antisense strand and a sense strand, wherein the siRNA molecule has at least one single nucleotide bulge formed by introducing a single nucleotide into the antisense strand, particularly at position 2 from the 5′ end, and to a method of using the same to silence a target gene. The siRNA molecule of the invention shows high target gene silencing efficiency while minimizing off-target effects caused by the antisense strand, and thus has improved target selectivity. Accordingly, the siRNA molecule of the invention can be substituted for conventional siRNA molecules and can be widely be used in siRNA-based gene silencing techniques, including gene therapy.05-23-2013
20130130380PLATFORM OF DENDRITIC CELL (DC)-BASED VACCINATION - The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.05-23-2013
20130130379AMINO ACID SEQUENCES DIRECTED AGAINST GPCRS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF GPCR-RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.05-23-2013
20130143321METHOD OF INDUCING DIFFERENTIATION FROM PLURIPOTENT STEM CELLS TO GERM CELLS - This invention provides a method of producing an epiblast-like cell (EpiLC) from a pluripotent stem cell, which comprises culturing the pluripotent stem cell in the presence of activin A; a method of producing a primordial germ cell-like (PGC-like) cell a pluripotent stem cell, which comprises culturing the EpiLC obtained by the method above in the presence of BMP4 and LIF. Also provided are a cell population containing PGC-like cells as obtained by the method, and reagent kits for the EpiLC- and PGC-like cell-induction from a pluripotent stem cell.06-06-2013
20130177983METHODS AND COMPOSITIONS FOR REGULATION OF TRANSGENE EXPRESSION - Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.07-11-2013
20100279409METHOD FOR MODIFYING CELLUAR IMMUNE RESONSE BY MODULATING ACTIVIN ACTIVITY - The invention relates to methods for modifying a cellular response, such as a CD811-04-2010
20100279408POLYMERIC SHORT INTERFERING RNA CONJUGATES - The present invention provides polymeric siRNA conjugates. Methods for down-regulation of gene expression in vivo and in vitro and for inhibition of the growth of cancer cells using the conjugates are also disclosed.11-04-2010
20100279410COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention relates to compounds of structural formula (I):11-04-2010
20100279407ALPHA 1-ACID GLYCOPROTEIN, ALPHA 2-HS GLYCOPROTEIN, ALPHA 1-ANTITRYPSIN, AND FRAGMENTS THEREOF INDUCE APOPTOSIS IN CANCER CELL LINES - This invention characterizes the selective apoptotic activity of specially prepared zinc charged alpha 1-acid glycoprotein, alpha 2-HS glycoprotein, and alpha 1-antitrypsin. These proteins cause apoptosis in cancer cells while leaving normal cells intact. In addition, active fragments of zinc charged alpha 1-acid glycoprotein and alpha 2-HS glycoprotein, whether manufactured from the modification of natural alpha 1-acid glycoprotein or alpha 2-HS glycoprotein, recombinantly, or synthetically, selectively induce apoptosis.11-04-2010
20080199957ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontophoresis, and/or electrophoresis can also be used with the disrupting agents.08-21-2008
20110223666CYTOPLASM EXPOSURE ADDITIVE AND METHOD FOR EXPOSING PARTICLES DELIVERED INTO CELL TO CYTOPLASM FROM ENDOCYTIC VESICLES IN INTACT CELL - The present invention relates to a method of exposing particles to cytoplasm comprising introducing particles into a live cell; allowing the live cell to contact a cytoplasm exposure additive which can expose the particles from endocytic vesicles to cytoplasm in the cell with maintaining its physiological, biochemical, or biological environment as undamaged; and allowing the particles to be exposed from the endocytic vesicles to the cytoplasm. The present invention is advantageous in that particles delivered into cells can be effectively exposed to cytoplasm from endocytic vesicles in intact cells which maintain their physiological, biochemical, or biological environment as undamaged.09-15-2011
20110236975GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK - The present invention provides for isolated polypeptides capable of binding ErbB-4.09-29-2011
20130149780Nucleotide-Specific Recognition Sequences For Designer TAL Effectors - The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.06-13-2013
20130149781Nucleotide-Specific Recognition Sequences For Designer TAL Effectors - The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.06-13-2013
20130149779COMBINATIONS OF PROTEINS TO ENHANCE VIABILITY OF STEM CELLS AND THEIR PROGENITORS BEFORE TRANSPLANTATION - Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human α06-13-2013
20100297762PHOTODYNAMIC THERAPY USING CHEMILUMINESCENCE AND A LIGAND-PHOTOSENSITISER CONJUGATE - A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.11-25-2010
20100317111CD40 AGONIST ANTIBODY/TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY - A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.12-16-2010
20100317110CELL-MEDIATED DELIVERY AND TARGETED EROSION OF NONCOVALENTLY CROSSLINKED HYDROGELS - A method for targeted delivery of therapeutic compounds from hydrogels is presented. The method involves administering to a cell a hydrogel in which a therapeutic compound is noncovalently bound to heparin.12-16-2010
20100317109FACTOR - Provided is a method of producing neurite outgrowth and/or development using RARβ2 and/or an agonist thereof.12-16-2010
20130157363METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS - The present invention provides methods for producing cell populations enriched for stable, regulatory T cells (Tregs). In particular, the invention relates to methods for culturing T cells such that the final culture is enriched for stable, regulatory T cells. It also relates to methods for stabilizing regulatory T cells. Also provided are compositions enriched for stable, regulatory T cells, which are useful for treating individuals in need of such treatment. The methods and compositions disclosed herein can also be used to treat an individual suffering from an immune-mediated disease.06-20-2013
20130157364MEDIUM COMPOSITION FOR CULTURING SELF-ACTIVATED LYMPHOCYTES AND METHOD FOR CULTURING SELF-ACTIVATED LYMPHOCYTES USING SAME - Disclosed is a medium composition for culturing self-activated lymphocytes, which contains anti-CD3 antibody and anti-CD16 antibody in addition to interleukin 2 (IL-2), interleukin 12 (IL-12) and interleukin 18 (IL-18) in a medium, and thus can efficiently proliferate and activate NK cells, T cells and NKT cells and, at the same time, can significantly increase the ratio of NK cells in lymphocytes so as to provide immunocytes having excellent effects on the treatment of various kinds of malignant tumors, and a method for culturing self-activated lymphocytes using the medium composition.06-20-2013
20120282696FUNCTIONS AND TARGETS OF LET-7 MICRO RNAS - The present invention concerns methods and compositions for treating or assessing treatment of diseases related to mis-expression of genes or genetic pathways that can be modulated by let-7. Methods may include evaluating patients for genes or genetic pathways modulated by let-7, and/or using an expression profile to assess the condition of a patient or treating the patient with an appropriate miRNA.11-08-2012
20120282695CONSTRUCTS FOR ENHANCEMENT OF GENE EXPRESSION IN MUSCLE - Efficient and muscle-specific gene expression can be obtained with constructs containing two or more copies of USE and/or ΔUSE fused to the minimal promoter of the TnISlow gene. USE is a small (about 160-bp) upstream enhancer of the TnISlow gene that confers slow-twitch muscle fiber specificity. ΔUSE is generated from a 100-bp deletion at the 5′ end of USE. ΔUSE confers expression in slow- and fast-twitch muscle fibers. The strength and relatively small size (less than 600-bp) of these constructs make them useful for gene therapy applications.11-08-2012
20110312093COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-BETA PEPTIDE-RELATED DISORDERS - The present invention provides methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate Aβ levels. The invention also provides modulation of Aβ levels via selective modulation (e.g., inhibition) of ATP-dependent γ-secretase activity. The invention also provides methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a modulator of γ-secretase, including, but not limited to, a selective inhibitor of ATP-dependent γ-secretase activity or an agent that decreases the formation of active (or optimally active) γ-secretase. The invention also provides the use of inhibitors of ATP-dependent γ-secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.12-22-2011
20130189780REPROGRAMMING COMPOSITIONS - The present invention provides compositions and methods of using the compositions to alter the developmental potency of a cell. The present invention provides in vivo and ex vivo cell reprogramming or dedifferentiation methods suitable for autologous cell therapy and regenerative medicine.07-25-2013
20130189781LOSS OF DE NOVO DNA METHYLTRANSFERASES PROMOTES EXPANSION OF NORMAL HEMATOPOIETIC STEM CELLS - Methods and compositions related to increasing expansion of stem cells, such as hematopoietic stem cells (HSCs), via inhibition of at least one of two de novo DNA methyltransferase enzymes, DNMT3a and/or DNMT3b are disclosed.07-25-2013
20130189782COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN - Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.07-25-2013
20130189783METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 - The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via β1 integrin activation.07-25-2013
20130189784ANTI-HEPARAN SULFATE PEPTIDES THAT BLOCK HERPES SIMPLEX VIRUS INFECTION IN VIVO - Provided are anti-heparan sulfate peptides and methods that employ those peptides for the prevention or treatment of viral infections, including herpesviral infections such as α-herpesviral, β-herpesviral, and γ-herpesviral infections, which are exemplified by HSV-1. CMV, and HHV-8 viral infections, respectively. Peptides may comprise at least 10 amino acids of the amino acid sequences X07-25-2013
20120021516NOVEL STRUCTURALLY DESIGNED shRNAs - Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.01-26-2012
20120021515OLIGOMERIC COMPOUNDS AND METHODS - The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds, as RNAi compounds, and/or as modulators of splicing.01-26-2012
20120021514HETEROGENEOUS POLYMERIC MICELLES FOR INTRACELLULAR DELIVERY - Compositions comprising a heterogeneous polymeric micelle and an agent (e.g., a polynucleotide) associated with the micelle are disclosed, together with methods for intracellular delivery of such agent.01-26-2012
20130196432BIOLOGICALLY ACTIVE MOLECULES FOR INFLUENCING VIRUS-, BACTERIA-, PARASITE-INFECTED CELLS AND/OR TUMOR CELLS AND METHOD FOR THE USE THEREOF - The aim of the invention is to effectively inhibit virus-, bacteria-, or parasite-infected cells and tumor cells in a targeted manner, even in the case of mutations. According to the invention, biologically active molecules are administered, said biologically active molecules including at least one protease inhibitor for at least one specific target protease of the virus-, bacteria-, or parasite-infected cells and/or tumor cells and at least one peptide-inhibited siRNA, PNA or RNA, the peptide bond of which is broken by the at least one target protease for the purpose of activating the peptide-inhibited siRNA, PNA or RNA. The molecules are used, for example, to influence the gene expression of diseased and infected organs or cells.08-01-2013
20130196433Boronate-Mediated Delivery of Molecules into Cells - Methods for enhancing cellular uptake of cargo molecules by boronating the cargo molecule, particularly with one or more phenylboronic acid groups. Cellular uptake includes at least partial uptake into the cytosol. Boronation includes ligating, crosslinking or otherwise bonding one or more phenylboronic acids substituted to contain a reactive group to a cargo molecule. Boronation also includes ligating, crosslinking or otherwise bonding a phenylboronated oligopeptide to a cargo molecule. The phenylboronate groups are optionally conjugated to the cargo molecule via linking moieties that can be selectively cleaved, such cleavable linkers can allow the phenylboronate groups to be removed from the cargo molecule after the boronated cargo molecule is introduced into the cell. The invention includes certain phenylboronates which are boronation reagents, certain boronated oligopeptides and certain boronated peptides and proteins. The invention also includes kits for enhancing cellular uptake of cargo molecules by boronation with one or more phenylboronates or boronated oligopeptides.08-01-2013
20130196434ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND - One aspect of the present invention relates to a double stranded nucleic acid useful as an siRNA, that has a sense strand and an antisense strand relative to a target nucleic acid, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one nucleoside comprising a non-natural nucleobase. Another aspect of the invention relates to a method of gene silencing, comprising administering to a mammal in need thereof a therapeutically effective amount of a double-stranded oligonucleotides containing a sense strand and an antisense strand, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand.08-01-2013
20120295350Prospective Identification and Characterization of Breast Cancer Stem Cells - The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4(D114) or other Notch pathway components. The solid tumor may comprise solid tumor stem cells.11-22-2012
20130203167METHOD FOR INHIBITING THE FORMATION OF SET1 FAMILY CORE COMPLEXES - Disclosed in this specification is a method for inhibiting the formation of vertebrate SET1 family core complexes. A guanidinium-containing molecule is used to competitively inhibit the binding of the N-SET region of a SET1 protein to WDR5, thus inhibiting the formation of the SET1 family core complex. The guanidinium-containing molecule may be, for example, an arginine-containing peptide.08-08-2013
20090148945Novel Biodegradable Elastomeric Scaffold for Tissue Engineering and Light Scattering Fingerprinting Methods for Testing the Same - The present invention is directed to a novel biocompatible polymer that may be used in tissue engineering. More specifically, the specification describes methods and compositions for making and using a citric acid copolymers.06-11-2009
20130210144PROTEOLYTICALLY RESISTANT HYDROGEN BOND SURROGATE HELICES - The present invention relates to peptidomimetics having a stable, internally constrained protein secondary structure, where the peptidomimetics contain a hydrogen bond surrogate in the internal constraint, and at least one beta amino acid. Methods for promoting cell death using peptidomimetics that inhibit p53/hDM2 are also disclosed.08-15-2013

Patent applications in class Method of regulating cell metabolism or physiology

Patent applications in all subclasses Method of regulating cell metabolism or physiology